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ABSTRACT 
Title: A STUDY ON INFLUENCE OF IRON DEFICIENCY 
ANAEMIA OVER HBA1C LEVELS 
Background  
Iron deficiency anemia is the commonest nutritional anemia 
worldwide. HbA1c, which is a valuable tool in monitoring the glycemic 
control, has been recently recommended for diagnosing diabetes. HbA1c 
can be affected by other non glycemic parameters like hemoglobin 
variants, anemia, uremia, pregnancy and acute blood loss. Reports on the 
effects of iron deficiency anemia on HbA1c levels were inconsistent. 
Aim 
This study aims to study the levels of HbA1c in iron deficiency 
anemia patients and to study the changes in HbA1c levels after correction 
of anemia. 
Methods 
120 patients confirmed to have iron deficiency were enrolled in this 
study. Complete blood count, anemia profile including serum ferritin and 
 
 
HbA1c levels were measured at baseline and after treatment of anemia. 
These values were compared with those in the control population. 
Results 
The mean HbA1c level in iron deficiency anemia patients  
(4.619 ± 0.308%) was significantly lower than control group  
(5.446 ± 0.281%). A significant increase (5.816 ± 0.323%) was observed 
in the mean HbA1c of anemia group after treatment.  
Conclusions 
Our study showed that HbA1c levels were affected by iron 
deficiency anemia. The HbA1c levels are lower in iron deficiency anemia 
patients and it increases after treatment with iron supplements. So iron 
deficiency anemia has to be kept in mind before using the HbA1c to 
diagnose diabetes. 
Keywords: Iron deficiency anemia, HbA1c, ferritin.  
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INTRODUCTION 
Iron deficiency anemia is the commonest form of nutritional 
anemia worldwide. WHO (World Health Organization) reported that, 
globally there are 2.1 billion cases of iron deficiency anemia, which is 
approximately 30% of the world population.  
          Anemia is a late indicator of iron deficiency. It is estimated that 
iron deficiency is 2.5 times more common than anemia. 
           In developing countries the estimated prevalence of anemia was in 
children below 5 years 39%, in children between 5 to 14 years 48%, in 
women 15-59 years 42%, in men 15-59 years 30% and in adults more 
than 60 years of age group 45%. These figures show the significant 
impact of anemia on economic and health consequences for middle and 
low income countries. 
           Anemia and iron deficiency lead to significant productivity losses 
in adults. Iron deficiency in pregnant women is associated with increased 
maternal mortality, preterm labour, low birth weight and increased infant 
mortality. Iron deficiency in children leads to defective cognitive and 
motor development and increases susceptibility to infections. 
           Anemia is the major public health problem in India. According to 
National Family Health Survey (NFHS), 70% of children aged 6-59 
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months, 55% of females aged 15-49 years and 24% of males aged 15-49 
years were suffering from anemia. NFHS-3 data showed that the 
prevalence of anemia was higher in rural areas. But there is a paucity of 
data about the epidemiology of anemia in rural population.  
          Hemoglobin A1c (HbA1c) or glycated hemoglobin is the 
predominant fraction of hemoglobin A. It is used as the gold standard 
method for assessing the glycemic control. It reflects the glycemic status 
of the individual over the past 3 months. It is formed by glycation of 
NH2-terminal valine of the hemoglobin β chain.  
          According to the guidelines of American Diabetic Association, the 
target HbA1c in all diabetic patients is below 7%, to prevent the 
development of secondary microvascular complications. Similar to 
plasma glucose, HbA1c level is related to the prevalent retinopathy.      
         The ADA and an International Expert Committee have now 
recommended the use of HbA1c to diagnose diabetes. The WHO also 
agreed that HbA1c may be used to diagnose diabetes, with appropriate 
measures i.e. standardized assay, calibration against IFCC standards and 
low coefficient of variability.  
          In 2009, an International Expert Committee recommended the 
HbA1c level of more than 6.5% as a cut-off point to diagnose diabetes. 
The test should be repeated to confirm the diagnosis. Repeat testing is not 
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required if there are classical clinical symptoms and the plasma glucose 
levels more than 200 mg/dl. The Committee also recommended, 
considering the diabetes preventive measures in individuals with HbA1c 
level between 6.0 to 6.5%, as they are at a higher risk. 
           In addition to blood glucose level, HbA1c is affected by multiple 
factors like genetic, hematologic and illness related factors. 
           Initial studies suggested a relationship between HbA1c levels and 
iron deficiency anemia. They tried to explain that on the basis of 
structural modifications and alterations in HbA1c levels in old and new 
red blood cells. Few studies reported no differences in the HbA1c levels 
of anemic patients compared to healthy controls.  
          Few studies stated that higher HbA1c levels were seen in iron 
deficiency anemia patients and it decreased significantly after treatment. 
The results of various studies on relationship between HbA1c and iron 
deficiency anemia were conflicting. Only fewer studies have been 
conducted in Indian population on this topic. 
           Our aim is to study the levels of HbA1c in iron deficiency anemia 
patients and the changes in HbA1c level after the correction of iron 
deficiency anemia.  
 
AIMS
AND
OBJECTIVES
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AIMS AND OBJECTIVES 
Primary Objective 
To study the levels of HbA1c in iron deficiency anemia patients. 
Secondary Objective 
          To study the changes in HbA1c level with the correction of iron 
deficiency anemia. 
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REVIEW OF LITERATURE 
IRON DEFICIENCY 
Iron deficiency is the state in which the iron content of the body is 
less than normal. The earliest stage of iron deficiency is depletion of iron 
stores, in which the serum iron, transferrin saturation and hemoglobin 
levels will be normal but the storage iron is decreased or absent. Further 
advanced stage is iron deficiency without anemia, characterized by 
depleted iron stores, low serum iron and transferrin saturation but without 
anemia.
(2) 
          Iron deficiency anemia is the far most advanced stage of iron 
deficiency. It is characterized by absent iron stores, low serum iron levels, 
low transferrin saturation with low hemoglobin levels.  
          Iron deficiency anemia is most prevalent in women and children in 
regions where meat intake is low, food is not fortified with iron, malaria, 
intestinal infections and parasitic worms are common. 
IRON METABOLISM 
Iron is one of the key elements in the basal metabolism. Iron is an 
important component of heme. It acts as the active site for electron 
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transport in cytochromes and cytochrome oxidase involved in energy 
generation in mitochondria. The heme moiety in hemoglobin and 
myoglobin binds with O2 thereby transfers O2 from the lungs to the 
various tissues and to store it. Heme is the active site in peroxidases, the 
enzymes involved in protection of cells from oxidative injury by reducing 
the peroxides to water and generate microbicidal hypochlorite in 
granulocytes. 
Table 3.1 Iron compartments 
 
DISTRIBUTION OF IRON 
I. HEMOGLOBIN 
Hemoglobin contains approximately2 gm of body iron in men and 
1.5 gm in women. One ml of packed red cells contains approximately 
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1mg of iron. As the life span of red cells is 120 days, everyday 1/120 of 
the iron in hemoglobin is recycled by macrophages and they are returned 
to the plasma. From plasma they are delivered mostly to marrow 
erythroblasts for incorporation into newly synthesized hemoglobin. 
II. STORAGE COMPARTMENT 
          The storage form of iron is ferritin or hemosiderin. Ferritin is water 
soluble and hemosiderin is water insoluble.  
FERRITIN 
The ferritin molecules have H (heavy), L (light) type subunits.  
H subunits have ferroxidase activity, which favors iron uptake or release 
by ferritin quite rapidly.  
Total iron store of the body is represented by plasma ferritin 
concentration, except during inflammatory conditions. The iron storage 
compartment in normal adult male is ~ 800 to 2000 mg, in adult female it 
is ~300-500 milligrams. 
          To mobilize iron from ferritin storage it has to be reduced from 
Fe3+ to Fe2+ which diffuses out of the apoferritin shell. It gets reoxidized 
by hephaestin or ceruloplasmin as it diffuses in to plasma from cytosol. 
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Then it binds to transferrin. Iron can also be released from ferritin by 
autophagy following lysosomal degradation. 
HEMOSIDERIN 
Hemosiderin is present abundantly in macrophages. It is similar to 
the iron core of ferritin chemically. It may be derived from ferritins, 
whose protein shells have been degraded in lysosomes. 
III. MYOGLOBIN 
          Myoglobin is present in all skeletal and cardiac muscles in small 
amounts. It serves as an oxygen reservoir. It protects the cells from 
hypoxic injury. It also scavenges nitric oxide and reactive oxygen species. 
IV. LABILE IRON POOL 
          It represents iron in the interstitial compartment before getting 
incorporated into heme or storage compounds. Some of the iron reenters 
the plasma. Normally, the labile iron pool is 80 - 90 mg.  
V. TISSUE-IRON COMPARTMENT 
          This amounts to 6 - 8 mg approximately (exclusive of hemoglobin, 
ferritin, hemosiderin, myoglobin and the labile compartment). 
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Cytochromes and other enzymes containing iron constitute tissue iron. It 
is one of the critical parts of the iron compartments. 
VI. TRANSPORT COMPARTMENT 
          It is the smallest, normally about 3 mg, but very active part of the 
iron compartments. This part of iron is almost entirely carried by 
transferrin. Transferrin turns over minimum 10 times per day normally. 
This transports iron between various compartments. 
TRANSFERRIN 
           Transferrin is a glycoprotein with two globular domains with 
binding clefts for Fe3+. Human plasma contains 200 to 360 mg/dl of 
transferrin, capable of binding 250 to 480 mcg/dl of iron, but carrying 
only 50 to 180 mcg/dl of iron. Transferrin is derived from apotrasferrin, 
which is devoid of iron, in hepatocytes and the cells of monocyte-
macrophage system. 
DIETARY IRON 
IRON CONTENT 
           Average adult men and women ingest 9 to 10 mg and 12 to 14 mg 
of iron per day, respectively. The iron requirement of an adult male is to 
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balance the small amount that is excreted via stool, ~ 1mg per day. Iron 
requirement is increased during active growth periods or after blood loss. 
In women, due to menstruation or diversion of iron to the fetus during 
pregnancy or lactation raises the iron requirement.  
Table 3.2 Recommended Dietary Allowances (RDAs) - for Iron 
 
BIOAVAILABILITY 
In non vegetarians, heme from hemoglobin and myoglobin 
comprises approximately 15 % of dietary iron, which is more efficiently 
absorbed than non-heme iron. The absorption of non heme iron is 
affected by iron binding components in food like Phytates, Oxalates, and 
Phosphates. These substances bind with iron and decrease its absorption.  
Iron absorption is increased by reducing substances (ascorbate, pyruvate, 
lactate, succinate, fructose, hydroquinone, cysteine and sorbitol). 
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          Iron fortified cereals act as major sources of iron in countries where 
fortification is practiced. Cooking in iron pots also provide important 
exogenous iron. Gastric pH, mucus secretion and the transit time for food 
particles in the intestine also affect iron absorption. 
IRON ABSORPTION 
          Majority of iron is absorbed in the duodenum. The absorption of 
iron depends on the body needs.  
         Iron absorption, 
Increased in : active red cell production and/or iron deficiency. 
Decreased in : iron overload states and systemic inflammation. 
 
Figure 3.1The relationship between oral iron dosage and amount of 
iron absorbed 
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TRANSPORT ACROSS INTESTINAL MUCOSA 
Ferric iron is reduced by duodenal cytochrome b reductase to 
ferrous iron. It is then transported into the intestinal villous cell by the 
Divalent metal transporter (DMT).  Ferroportin(Fpn) in association with 
hepaestin and ceruloplasmin oxidizes the iron back to the ferric form, 
which is exported across the basolateral membrane. Then ferric iron is 
transported by plasma apotransferrin.    
 
Figure 3.2 Schematic diagram of iron uptake
(5)  
dcytb –duodenal cytochrome-b, HCP-1 – Heme carrier protein-1, HO-Heme Oxygenase,  
DMT – Divalent metal transporter.
  
 
IRON RECYCLING 
          The destruction and production of RBCs generates most of the iron 
flux in and out of plasma, which approximates 20 to 25 mg/day recycled 
 
 
13 
in adults compared to its 1 to 2 mg/day of absorption. Destruction of the 
senescent erythrocytes and the degradation of hemoglobin occur within 
the monocyte-macrophage system. This occurs at a rate required to 
release ~20 % of the hemoglobin iron within a few hours. Among that, 
80% of the iron is reincorporated into the hemoglobin. The remaining 
iron is stored as ferritin or hemosiderin. 
          The stored iron can be mobilized rapidly if there is need for Hb 
synthesis. Infections and other inflammatory processes will slow this 
reusage of iron leading to anemia. 
HEPCIDIN 
Hepcidin, a peptide hormone, is produced predominantly by 
hepatocytes. It plays a major role in systemic iron homeostasis. 
Depending on the level of plasma iron concentration, Hepcidin tightly 
regulates the absorption of iron by the intestinal epithelial cells and its 
release from iron storage. 
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Figure 3.3 Regulation of plasma iron concentration by  
hepcidin
(2)Fpn- ferroportin; Tf- transferrin. 
 
IRON EXCRETION 
Our body conserves iron effectively. About 1mg of iron is lost via 
feces everyday secondary to desquamation of intestinal epithelial cells. 
Other smaller losses occur through skin exfoliation and dermal 
appendages and sweating. In women menstruation leads to negative iron 
balance. Average total iron loss per day in male is 1mg, whereas in 
menstruating female it is 2mg. During iron overload states daily loss can 
be as much as 4mg. 
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ETIOLOGY AND PATHOGENESIS OF IDA 
ETIOLOGY 
I.  Sources of blood loss: 
A.Alimentary 
tract: 
1.Esophagus-  Varices, 
 Erosions 
2.Stomach and 
duodenum- 
 Ulcer, 
 Gastritis, 
 Carcinoma,  
 Angiodysplasia, 
 Hemangioma, 
 Antralvascular ectasia, 
 Hypergastrinemia,  
 Watermelon stomach. 
3.Small intestine  Vascular ectasia,  
 Tumors,  
 Ulceration, 
 Meckel’s  diverticulum 
4.Colon and 
anorectal 
 
 Hemorrhoids,  
 Carcinoma,  
 Polyp, 
 Diverticuum,  
 Ulcerative colitis,  
 Angiodysplasia,  
 Hemangioma, 
 Telangiectasia,  
 Amoebiasis 
B.Biliarytract  Intrahepatic 
bleeding, 
 Carcinoma, 
 Cholelithiasis,  
 Trauma, 
 Ruptured aneurysm,  
 Aberrant pancreas 
 
 C.Genitourinary 
tract 
 Menorrhagia,  
 Uterine fibroids 
 Endometriosis,  
 
 Carcinoma, 
 Vascular abnormalities 
 D.Respiratory 
tract  
 Epistaxis, 
 Carcinoma 
 Infections 
 Telangiectases,  
 Idiopathic pulmonary 
hemosiderosis 
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II.  Increased demand: 
A. Rapid growth during infancy 
or adolescence 
 
B. Pregnancy and parturition In addition to hemodilution in 
pregnancy, true iron deficiency 
results in more severe anemia.  
 
III.  Dietary iron deficiency  
IV. Malabsorption of iron 
A. Due to Disease  
      
1. Sprue, 
2. Crohn’s diease 
B. Due to Surgery 1. Gastrectomy and  
2. Forms of bariatric surgery 
 
V.  Genetic factors 
VI.  Acute or chronic inflammation 
PATHOGENESIS 
 
Figure 3.4 Stages in the development of iron deficiency anemia
(6) 
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IRON CONTAINING PROTEINS 
In initial stage of iron deficiency, Storage iron in the body becomes 
depleted. That leads to dyserythropoiesis resulting in hemoglobin 
deficient erythrocytes. The concentration of other iron containing proteins 
like myoglobin, cytochromes and other mitochondrial ferroproteins are 
affected in an organ specific manner. 
MUSCULAR FUNCTION AND EXERCISE TOLERANCE 
Patients experience difficulty in performing high intensity exercise 
even during non anemic iron deficiency state, which worsens with 
increasing anemia. This exercise limitation results from reduced 
hemoglobin content of blood and decreased oxygen delivery to tissues. 
There will be decreased spontaneous activity, decreased ventilatory 
threshold, decreased endurance and increased muscle fatigue. These 
effects are attributed to the depletion of iron containing mitochondrial 
proteins involved in energy metabolism. These effects are reversible with 
iron supplementation. 
NEUROLOGIC CHANGES 
             Iron deficiency is associated with developmental abnormalities in 
children. In adults it is associated with restless leg syndrome. 
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HOST DEFENSE AND INFLAMMATION 
Iron deficiency acts as a pro inflammatory state. It affects various 
immune functions through hepcidin. Iron deficiency potentiated the 
systemic effect of lipopolysaccharide in a hepcidin dependant manner. 
And it also promoted allergic inflammation like asthma.   
GROWTH AND METABOLISM 
Reports state that iron deficiency in children leads to growth 
retardation. There will be decreased thermoregulation in response to 
exposure to cold. This is attributed to the conflicting effects of blood flow 
with decreased oxygen content and need to minimize heat loss and also 
the effect on thyroid function. 
HISTOLOGIC FINDINGS 
          Iron deficiency, depending on the severity leads to histological 
changes in various body organs. It commonly affects the rapidly 
proliferating cells in the upper part of gastro intestinal tract. There will be 
mucosal atrophy in the upper GI tract. The epithelial thickness of the 
lateral margin of the tongue is decreased despite increase in progenitor 
compartment, reflecting accelerated exfoliation of epithelial cells. There 
is thinning and keratinization of buccal mucosa with increased mitotic 
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activity. Widening of diploic spaces of bones like skull and hands will 
occur in chronic iron deficiency beginning in infancy. 
CLINICAL FEATURES 
Symptoms of anemia result from decreased oxygen supply to cells 
and the body’s response to it. Resulting tachycardia can be perceived as 
palpitations and pounding sensations in ears, headache, light headedness. 
Rarely angina can occur if the anemia is very severe. 
Neurological 
Decreased work performance will be seen. In infants and children, 
iron deficiency may lead to poor attention, retarded behavioral and 
developmental milestones. Iron deficiency also contributes to tourette 
syndrome, attention deficit hyperactivity disorder and restless leg 
syndrome. 
          Breath holding spells in children, headaches and paresthesias have 
been attributed to iron deficiency. Association has been found between 
iron deficiency anemia and thrombocytosis that possibly triggers stroke in 
children and adults. 
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Alimentary tract 
Iron deficiency accounts for burning sensation in tongue which 
diminishes with treatment. It could be a result of coexisting pyridoxine 
deficiency.  
         Mucosal atrophy in the laryngo pharynx leads to formation of post 
cricoids web, which results in difficulty in swallowing (Plummer Vinson 
syndrome). If it persists for longer duration, this condition may lead to 
pharyngeal carcinoma.  
PICA 
Pica is a well documented manifestation of iron deficiency. Pica is 
increased desire to eat unusual (unhealthy) substances like clay, paint, 
laundry starch, cardboard and even hair. It is promptly cured by iron 
therapy.  
PHYSICAL SIGNS 
         The physical signs seen are pallor, smooth, red tongue, stomatitis / 
angular cheilitis and spooning of nails. Fundus examination of the 
severely anemic patients may reveal hemorrhages/exudates in retina.  
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LABORATORY FINDINGS 
BLOOD CELLS 
ERYTHROCYTES 
In iron deficiency anemia the earliest recognizable morphologic 
change of red blood cell is anisocytosis. It may be accompanied by mild 
ovalocytosis. 
                              
Figure 3.5 Peripheral smear in iron deficiency anemia 
Initially mild normocytic normochromic anemia develops. As the 
iron deficiency progresses, erythrocyte count, mean corpuscular volume, 
mean hemoglobin concentration, mean erythrocyte hemoglobin content 
all decline together. As these indices change, red cells appear microcytic 
and hypochromic. Sometimes target cells, pencil cells may be seen.  
          The distribution of red cell volume (i.e. red cell distribution width- 
RDW) is increased in iron deficiency anemia. 
Microcytic and 
hypochromic 
Anisopoikilocytosis
ss 
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LEUKOCYTES 
Some patients may have leucopenia, but most people with iron 
deficiency anemia have normal white cell count. 
PLATELETS 
Iron deficiency anemia can be associated with both 
thrombocytopenia and thrombocytosis, though the mechanism is 
unknown.  
RETICULOCYTES 
Due to increased erythroid activity in the bone marrow reticulocyte 
count is often mildly increased.  
MARROW 
The iron stores are depleted earlier than the compromise in red cell 
mass in iron deficiency anemia. Thus evaluation of iron store is the most 
sensitive and reliable means of differentiating iron deficiency anemia 
from all other anemias. The characteristic finding in the marrow of iron 
deficiency is decreased or absent hemosiderin, which is evaluated by 
staining with Prussian blue method. The gold standard for diagnosing 
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iron deficiency is estimating the marrow macrophage iron content. It is 
altered by previous transfusion and treatment with parenteral iron.   
SERUM IRON CONCENTRATION 
In iron deficiency anemia, the serum iron concentration will be 
low, but rarely may be normal. The serum iron concentration has diurnal 
rhythm. It is maximum in morning between 7 to 10 am and decreases in 
late afternoon and evening. This diurnal rhythm may rarely influence the 
diagnosis. The serum iron concentration is altered in inflammatory 
conditions and malignancy. Conversely, it may be elevated during 
chemotherapy as the cytotoxic drugs inhibit erythropoiesis and related 
iron uptake by erythroblasts. Serum iron concentration will normal or 
even high if the patients have received iron medication before the 
investigation.  
IRON BINDING CAPACITY AND TRANSFERRIN SATURATION 
The total iron binding capacity represents the amount of transferrin 
in the blood. The unsaturated or latent iron binding capacity (UIBC) can 
be measured easily by spectrophotometric techniques. The sum of UIBC 
and the serum iron is total iron biding capacity (TIBC). In iron deficiency 
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anemia, both UIBC and TIBC are increased and serum iron concentration 
is decreased so the transferrin saturation is reduced.  
SERUM FERRITIN 
Serum ferritin concentration represents the total body iron stores. 
In iron deficiency state the serum ferritin level will be as low as 10mcg/L.  
Ferritin concentration is elevated in inflammatory disorders like 
rheumatoid arthritis, chronic kidney disease and malignancies. The 
normal serum ferritin value differs according to the age and gender.
(7) 
 
Figure 3.6 Serum ferritin levels as a function of sex and age 
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RED CELL PROTOPORPHYRIN LEVELS 
In iron deficiency anemia, heme synthesis is impaired leading to 
accumulation of protoporphyrin within the red cells. Normally it will be 
less than 30mcg/dl. In iron deficiency, the red cell protoporphyrin levels 
are more than 100mcg/dl.  
TRANSFERRIN RECEPTOR PROTEIN LEVELS 
Tranferrin receptors (TfR) are abundant in erythroid cells. The 
levels of circulating TfR correlate with the amount of cellular receptors, 
which is proportional to the number of erythroblasts expressing the 
receptor.  When cells lack iron, TfR synthesis is enhanced which results 
in increased circulating receptor levels. In anemia of inflammation the 
TfR synthesis is suppressed by cytokines. 
NOVEL ERYTHROCYTE INDICES 
       Reticulocyte Hemoglobin Content can be measured by automated 
instruments. It is an indicator of iron restriction of hemoglobin synthesis 
during 3 to 4 days prior to the test.  
        Percent hypochromic erythrocytes give a longer term assessment of 
iron restriction during the preceding few months.  
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DIFFERENTIAL DIAGNOSIS 
I. THALASSEMIA 
It results from an inherited defect in globin chain synthesis. It can 
be differentiated from iron deficiency by serum iron levels. The serum 
iron levels and the transferrin saturation levels will be normal or 
increased in thalassemias. The RDW index will be normal in thalassemia. 
It is elevated in iron deficiency anemia. 
II. ANEMIA OF CHRONIC INFLAMMATION  
It results from inadequate supply of iron to the erythroid marrow. 
Anemia of inflammation is usually normocytic and normochromic. The 
ferritin level may be normal or elevated. The percent transferrin 
saturation and TIBC are decreased in anemia of chronic disease. 
III. MYELODYSPLASTIC SYNDROMES:  
Myelodysplastic patients will have impaired hemoglobin synthesis 
with mitochondrial dysfunction, which leads to defective iron 
incorporation into heme. The iron store levels will be normal and excess.. 
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Table 3.3 Diagnosis of microcytic anemia 
 
TREATMENT 
The treatment approach to iron deficiency anemia varies according 
to the severity and cause. There are three major therapeutic approaches 
once the diagnosis and cause of iron deficiency is made.   
I.RED CELL TRANSFUSION 
Transfusion therapy is reserved for patients with 
 Symptomatic anemia 
 Hemodynamic instability 
 Continued/excessive blood loss  
 In patients requiring intervention      
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In these patients management is related to the consequences of the 
severe anemia than the iron deficiency. In addition to correcting the 
anemia transfusion provides iron for reutilization. 
II. ORAL IRON THERAPY 
Treatment with oral iron is adequate in asymptomatic patients with 
established iron deficiency anemia. There are multiple iron preparations 
available like simple salts to complex compounds designed for sustained 
release. Even though they contain various amount of iron, they are well 
absorbed and equally effective in treatment. Some preparations contain 
ascorbic acid to enhance the absorption of iron.  
          For iron replacement up to 200 mg of elemental iron is provided 
per day in divided doses. Food interferes with iron absorption. So the iron 
tablets are taken in empty stomach. From the 200 mg of provided iron 50 
mg will be absorbed per day.  
The amount of iron absorbed depends on  
- the hemoglobin level,  
- marrow function and  
- the degree of erythropoietin stimulus. 
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The goal of iron therapy is to correct the anemia and to provide at 
least 0.5 to 1 gm of iron stores. This goal requires continuous treatment 
for 6 to 12 months after correcting the anemia. 
          GI discomfort is the most common adverse effect with oral iron 
therapy. Nausea, vomiting, abdominal pain or constipation are the other 
adverse effects seen with oral iron preparations. These may lead to non 
compliance. Sustained release preparations or small doses of iron will 
have lower incidence of the gastrointestinal side effects.  
The response to oral iron depends on i) the erythropoietin stimulus 
and  ii) the rate of absorption.  Adequate response is indicated by the rise 
in reticulocyte count within 4-7 days after the initiation of therapy. 
Inadequate or absence of response may be seen in non compliance 
(commonest), poor absorption or a faulty diagnosis. 
Table 3.4 Oral preparations: 
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III. PARENTERAL IRON THERAPY 
Parenteral iron is reserved for patients with: 
- intolerance to oral iron 
- acute need 
- Ongoing iron requirement, secondary to continuous GI blood 
loss. 
Parenteral iron can be given in two ways  
i) Requirement of iron to correct the Hb deficit and to replace 
minimum 500 mg of iron stores is calculated and 
administered.  
ii) Regular small doses of parenteral iron are given as in 
patients on dialysis to improve the response to recombinant 
EPO. 
Formula for iron requirement calculation
(1)
: 
Body weight (kg) × 2.3 × (15 –patient’s hemoglobin, gm/dl) + 500 
or 1000 mg (for stores) 
          Anaphylaxis is the major concern with intravenous iron dextran. 
But with the availability of newer parenteral iron preparations 
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anaphylaxis has become much rarer. Other symptoms like arthralgias, 
skin rash and low grade fever may be seen. These symptoms are usually 
dose related. Further use of parenteral iron is not precluded in these 
patients. 
          Recommended test dose is 25 mg. Instead of separate test dose a 
slow infusion will provide early warning. Infusion of iron should be 
stopped immediately if the patient develops chest pain, breathing 
difficulty, hypotension or other allergic/anaphylactic symptoms.  
         Currently available parenteral iron preparations include iron 
sucrose, low molecular weight iron dextran, ferric gluconate, ferric 
carboxymaltose, ferumoxytol and iron isomaltose.  
Table 3.5 Parenteral iron preparations 
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IRON REFRACTORY IRON DEFICIENCY 
In some patients, even with adequate iron supplementation iron 
deficiency persists. The causes are i) poor compliance (most common), ii) 
wrong diagnosis, iii) continuing losses, iv) iron malabsorption secondary 
to celiac disease, autoimmune gastritis and H.Pylori infection, v)inherited 
defects in iron uptake, transfer and release.
(4) 
 
Figure 3.7 Approach to iron refractory iron deficiency 
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GLYCATED HEMOGLOBIN 
          Glycated hemoglobin (HbA1c) is a form of hemoglobin, modified 
with a stable adduct of glucose linked covalently to the N-terminal valine 
of the β-chain. In adults normal hemoglobin consists of HbA (α2β2), 
HbA2 (α2δ2) and HbF (α2γ2) in 97%, 2.5% and 0.5% respectively. 
Among the total HbA, about 6% is termed as HbA1. HbA1 consists of 
HbA1a1, HbA1a2, HbA1b and HbA1c. These fractions are characterized 
by their individual electrophoretic and chromatographic properties. 
Despite the identical amino acid sequences of HbA1 and HbA0, these 
fractions differ slightly in their electrophoretic and chromatographic 
properties from those of the major component HbA0.
(9) 
         HbA1c is the predominant HbA1 fraction. In healthy people it 
constitutes approximately 5% of the total HbA fraction. There is no 
known physiological role for HbA1c.  
ESTIMATION OF HbA1c
(9)
 
1. Cation exchange chromatography  
         HbA1c and HbA0 can be separated on the basis of the subtle 
difference in their isoelectric points. Nowadays High performance liquid 
chromatography (HPLC) systems were used, which are not affected from 
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interference by the Schiff base or carbamylated hemoglobin, but by the 
hemoglobin variants. 
2. Affinity chromatography 
         This assay method utilizes m-amino phenyl boronic acid. This 
method is based on the interaction between the glucose molecule on 
HbA1c and the boronic acid, which is immobilsed.  
3. Immunoassay 
          In this assay the antibodies are directed against the β N-terminal 
glycated tetrapeptide or hexapeptide group. Electrical charge does not 
affect this assay. It can be used in the routine medical laboratory. But 
they have drawback of requiring multilevel calibration and frequent 
recalibration.  
4. Capillary electrophoresis 
         This method is based on liquid flow capillary electrophoresis in 
free solution. This technique utilizes the principle of different 
electrophoretic mobility of charged molecules in an alkaline buffer at a 
particular pH. The separation of the fractions of hemoglobin occurs in 
silica capillary tubes and the migration is performed at the high voltage 
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under tight temperature control. The hemoglobins are detected directly at 
the cathode end at a specific absorption wavelength of 414nm by an 
optical detector.  
MARKER FOR GLYCEMIA 
         Primarily, glycated hemoglobin represents the average plasma 
glucose concentration over a period of 12 to 16 weeks.  The fraction of 
glycated hemoglobin increases in a predictable way as the average plasma 
glucose increases. Higher amount of glycated hemoglobin in diabetes 
mellitus indicates poor glycemic control.  
         Although hemoglobin glycation occurs throughout the life span of 
the red blood cell, major influence over the HbA1c value is by the recent 
glycemia. Mean blood glucose of the previous 1
st
, 2
nd
 and 3
rd
 month 
contributes about 50%, 40% and 10% respectively to the final HbA1c 
value. The t1/2 of HbA1c is approximately 35.2 days by mathematical 
remodeling. So, the previous 35.2 days have contributed to about half of 
the glycation. HbA1c gives us the assessment of average plasma glucose 
but not about the stability of glycemic control. So even with widely 
fluctuating glucose levels a patient can have the same HbA1c as one with 
little variation.  The approximate mapping between eAG (estimated 
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average glucose) measurements and HbA1c values is given by the 
equation: 
eAG (mg/dl) = 28.7 × A1C – 46.7 
eAG (mmol/l) = 1.59 × A1C – 2.59 
         While American Diabetes Association recommends the HbA1c 
below 7.0% as the target. American College of Endocrinology and the 
International Diabetes Federation recommend HbA1c below 6.5%. Target 
HbA1c level should be individualized. Patients at risk for developing 
diabetes associated complications have been proved to gain further 
benefits from reducing the HbA1c level below 7%. The American 
Diabetes Association advices to do the HbA1c test twice a year in 
diabetic patients who have achieved treatment goals and quarterly in 
those whose therapy has changed or not meeting the glycemic levels 
diagnosis of DM.  
HBA1C AND DIAGNOSIS OF DM 
         The hallmark of diabetes is chronic hyperglycemia resulting in 
diabetes specific complications. So the HbA1c which represents the 
longterm glucose exposure predicts the diabetes specific complications 
better than single glucose measurement. Studies proved a consistent and 
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significant correlation between retinopathy and HbA1c levels than with 
the fasting glucose levels
(16)
. Multiple controlled clinical trials and large 
volume of data from different populations have provided a strong 
evidence for assigning an HbA1c cut off point of more than 6.5% for 
diagnosing diabetes as this HbA1c level is associated with an increased 
prevalence of diabetes specific complications especially 
retinopathy
(15,19,25,29,62)
. This cut off point is not an absolute demarcation 
between diabetes and normal glycemic status. But this level is sensitive 
and specific to detect the patients at risk for developing retinopathy. An 
International Expert Committee has recommended the HbA1c level of 
more than 6.5% to diagnose diabetes
(21)
. The same has been affirmed by 
American Diabetes association
(61)
. But this diagnostic HbA1c test should 
be done by a standard method certified by the NGSP- National 
Glycohemoglobin Standardization Program
(8)
 and traceable or 
standardized to the Diabetes Control and Complications Trial (DCCT) 
reference assay.
(15,24,63)
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Table 3.6 American Diabetic Association (ADA) criteria for the 
diagnosis of diabetes
(22) 
 
ADVANTAGES OF HbA1c
(10)
   
1. HbA1c measures chronic hyperglycemia better than the two 
assessments of fasting glucose level or 2 hours OGTT 
Chronic hyperglycemia is the biochemical hallmark of diabetes. 
But fasting glucose and 2 hour OGTT gives just a momentary glycemic 
status of that day. In contrast, HbA1c provides the glycemic status over a 
longer duration (3 months).  
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2. HbA1c is better associated with chronic complications than 
FPG 
Diabetic glycemic levels have been proposed on the basis of their 
association with retinopathy.  Multiple studies showed that FPG levels 
around 126 mg/dl and 2 hour PG around 200 mg/dl have been associated 
with higher nonproliferative diabetic retinopathy prevalence. Those 
studies also documented increased prevalence of retinopathy with HbA1c 
levels around 6.5%.
(26,27,34) 
3. Fasting is not needed for HbA1c assessment and acute 
perturbations do not affect HbA1c 
Plasma glucose levels vary throughout the day. Multiple acute 
conditions could affect glucose homeostasis. Acute stress promotes 
neoglucogenesis and impairs the utilization of glucose. After exercise the 
glucose levels are decreased. Early morning and evening physical 
exertion might affect the fasting glucose levels. Smoking and certain drug 
intake could affect fasting glucose. Patient should not eat for 8 hrs before 
testing fasting glucose. So, without appropriate preparation fasting 
plasma glucose testing is less reliable for diagnosing diabetes. In 
contrary, HbA1c is not affected by those acute stressful events or duration 
of fasting. HbA1c can be measured at anytime of the day, irrespective of 
fasting.
(19,21,35)
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4. HbA1c has a greater pre analytical stability than plasma 
glucose 
There are potential pre analytic errors in the measurement of 
glucose. Samples stored at room temperature before analysis will result in 
reduction in glucose levels due to in vitro glycolysis. Glucose 
concentration decreases 5 to 7 % per hour and the rate increases if the 
ambient temperature is high. So the results will show lower glucose levels 
than they are and diagnosis of diabetes can be missed. In contrast HbA1c 
values are relatively stable after collection.
(15,21,61)
    
5. Biological variability of HbA1c is lower compared to FPG 
The variability of HbA1c values is negligible compared to fasting 
glucose levels. With day to day or person to person, variation is less than 
2% for HbA1c but 12 to 15% for FPG.
(15,21)
 
6. Standardization of HbA1c assay is not inferior to 
standardization of glucose assay 
The important concern about HbA1c was the poor standardization 
of the assays. An effective standardization program was made available 
to overcome this disadvantage
(24,63)
. The standardization of HbA1c assay 
minimized the laboratory based biases
(17)
. Moreover studies conducted 
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over various laboratories have clearly showed a significant laboratory 
based bias in glucose assessment, resulting in misclassification of glucose 
intolerance in 12% of subjects.
(61)
   
7. Individual susceptibility to glycation might be an additional 
benefit for HbA1c assessment 
Sometimes the HbA1c value could be lower or higher than the 
expected value in accordance with their glucose levels. The hemoglobin 
glycation index (HGI) is the difference between the observed and the 
predicted HbA1c levels. Depending on this index, the patients have been 
categorized as low, moderate or high HGI. Patients with high HGI have 
increased risk of micro and macro vascular complications even with 
better glycemic control. So the HbA1c assessment provides additional 
information about diabetes related complications.  
8. Using the same biomarker for diagnosing and monitoring 
HbA1c is used to monitor the degree of glycemic control. So the 
treatment strategies can be modified appropriately when the Hba1c values 
deviate from the target levels. When the HbA1c is used to diagnose 
diabetes, we already have a baseline HbA1c value. From that value 
further deviation from target can be assessed and managed effectively.  
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LIMITATIONS OF HBA1C 
1. Diabetes is defined by high blood glucose and not by glycation 
of proteins 
Diabetes is a clinical condition characterized by elevated plasma 
glucose concentration. High HbA1c level indicates higher level of 
glycation of proteins. Even though it occurs as a result of high plasma 
glucose, primary pathology has to be given importance over the 
secondary results. In addition, there will be delay in rising of HbA1c after 
an increase in plasma glucose level. So if we use HbA1c the diagnosis 
will be delayed compared to glucose measurement.  
2. HbA1c is a poor marker of important pathophysiological 
abnormalities featuring diabetes 
The pathophysiology of diabetes is better reflected by OGTT and 2 
hour post glucose levels. The plasma glucose levels are at the peak during 
the postprandial state. Essential functioning of the pancreatic β cell is 
required during that time. The information about the postprandial state is 
provided only by the OGTT and 2 hour plasma glucose tests. HbA1c 
provides information about chronic hyperglycemia alone. Good β cell 
capacity is indicated by normal blood glucose 2 hrs after glucose load. 
Vice versa higher levels indicate impaired β-cell function. Studies show 
that HbA1c is a weaker correlate of insulin resistance and insulin 
secretion compared with FPG and 2 hrs PG.  
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3. Factors that influence HbA1c and its measurement(12,31,61) 
1. Erythropoiesis: 
i)Increased HbA1c:  
 
 
ii)Decreased HbA1c: 
 
 Iron deficiency 
 Vitamin B12 deficiency, 
 Decreased erythropoiesis. 
 Administration of , iron, vitamin 
B12, Erythropoietin, 
  Reticulocytosis,  
 Chronic liver disease. 
2. Altered Hemoglobin: 
Genetic/chemical alterations in haemoglobin: haemoglobinopathies, 
HbF, methemoglobin - may increase or decrease HbA1c. 
3. Glycation: 
i)Increased HbA1c:  
 
ii)Decreased HbA1c: 
 
iii)Variable HbA1c:   
 
 Alcoholism,  
 Chronic renal failure.  
 Aspirin, vitamin C and E, 
 Certain haemoglobinopathies 
 Genetic determinants.(30) 
4. Erythrocyte destruction
(15)
: 
i)Increased HbA1c: 
 
ii)Decreased HbA1c:  
 
 Increased erythrocyte life span: 
Splenectomy  
 Decreased erythrocyte life span: 
 Hemoglobinopathies, 
 Splenomegaly,  
 Rheumatoid arthritis  
 Drugs such as antiretrovirals and 
dapsone. 
5. Assays  
i)Increased HbA1c:  
 
 
 
 
ii)Variable HbA1c: 
iii)Decreased HbA1c 
 
 Hyperbilirubinaemia,  
 Carbamylated haemoglobin, 
 Alcoholism,  
 Large doses of aspirin,  
 Chronic opiate use. 
 Haemoglobinopathies.(61) 
 Hypertriglyceridaemia. 
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4. HbA1c has a poor sensitivity in diagnosing diabetes and that 
would change the epidemiology 
OGTT identifies the asymptomatic diabetic cases and people with 
impaired glucose tolerance
(18)
. The diabetes preventive measures can be 
taken effectively in those patients. HbA1c cannot detect those cases.  
Epidemiological studies in the general population showed that 
fasting (~50%) and 2 hours plasma glucose levels (~90%) detects the 
previously undiagnosed diabetic patients effectively when compared to 
HbA1c (~30 to 40%).
(13,60)
 
5. 2 hrs PG and IGT are stronger predictors of CVD 
Fasting PG is a poor predictor of diabetes associated mortality and 
CVD events. But the 2 hrs PG and HbA1c are better predictors. Increased 
mortality (~40%) was seen in patients with impaired glucose tolerance. 
These people are not detected by measuring FPG or HbA1c levels. 
Effective measures in these patients will prevent/decrease the progression 
to diabetes. Thereby, the mortality risk is reduced. This cannot be made 
possible by measuring HbA1c or FPG.
(29)
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6. Fasting is not essential to identify the defects in glucose 
metabolism 
Excessive postprandial glucose excursion is the first sign of 
glucose homeostasis abnormality. And it predicts the cardiovascular 
outcome better, unlike fasting PG.  
7. Standardization of HbA1c assay is very poor 
Standardization of HbA1c assay has not been achieved worldwide 
yet. Inaccuracies in measurement are still a problem in many 
countries.
(17,24)
    
8. HbA1c assay is unreliable and cannot be used in many 
situations
(20,33)
 
HbA1c assays are affected by abnormality in Hemoglobin traits. 
Conditions affecting the life span of red cells will affect the HbA1c assay 
results
(13)
. These conditions will mislead the HbA1c assay results. There 
are ethnic differences and effect of aging
(30)
 in the relation between blood 
glucose and HbA1c
(11,12,29)
. HbA1c cannot be used if different cut off 
points are considered in all these conditions.
(36) 
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9. Day to day biological variability of plasma glucose might reveal 
disturbance of glucose metabolism 
Pathophysiological processes of type 2 diabetes may result in day 
to day variability in plasma glucose levels. It is also reflected by the 
individual’s dietary pattern and activities. HbA1c will not provide this 
information.   
10. Individual susceptibility to glycation of hemoglobin is not 
relevant 
As mentioned earlier individuals with high HGI are at risk for 
developing micro and macro vascular complications, even with good 
glycemic control compared to individuals with low HGI. This 
phenomenon is explained by postprandial glucose fluctuations. But 
HbA1c indicates only high mean exposure of hemoglobin to glucose. It 
does not provide information about the fluctuations in glucose levels.  
11.  Using the same biomarker for diagnosing and monitoring 
Many patients who are diagnosed as diabetic based on their glucose 
levels had HbA1c less than 6.5%
(23)
. So if HbA1c is used, these 
individuals are not diagnosed and left untreated.
(13,60)
  
12. Cost of the assay(23,24) 
HbA1c assays are more expensive. And they are not available in 
many countries.
(18) 
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EFFECTS OF IRON DEFICIENCY ANEMIA ON HbA1c LEVELS 
This study aims to measure the HbA1c levels in iron deficiency 
anemia patients and to identify the changes in HbA1c levels after 
correcting the iron deficiency anemia. Although, there were multiple 
studies in the past investigating the relationship between iron deficiency 
anemia and HbA1c, the results were inconsistent. 
Horton and Husiman
(39)
  performed one of the earliest studies in 
evaluating the influence of iron deficiency anemia over HbA1c levels. 
They showed that in patients with iron deficiency anemia the mean 
concentration of HbA1c was 4.9% compared to 5.3% in healthy 
individuals. 
Since 2000, there were studies evaluating the effects of iron 
deficiency anemia on HbA1c. In contrast to the earlier studies, HbA1c 
levels decreased as much as 17% after iron replacement according to 
these studies. It was postulated that there was a balance between serum 
glucose and HbA1c in normal individuals and if the serum glucose was 
maintained constant, a fall in hemoglobin could cause an increase in the 
Glycated fraction.
(45)
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Ford et al. conducted a study evaluating the influence of iron 
deficiency anemia over HbA1c levels. This study showed a positive 
association between HbA1c and hemoglobin levels. The mean HbA1c 
value in participants with Hb below 10 g/dl was 5.28% and in participants 
with Hb above 17 g/dl was 5.72%. The participants with and without iron 
deficiency had the adjusted mean HbA1c concentration of 5.56% and 
5.46% respectively with p value 0.095. They suggested that iron 
deficiency anemia had little effect on HbA1c levels. The difference in 
HbA1c concentrations between extremes of hemoglobin concentration 
was 0.2%. They concluded that, people who were close to the diagnostic 
threshold with anemia should be retested or undergo another diagnostic 
method.
(53)
  
          A study conducted by Sinha et al. compared the HbA1c levels in 
iron deficiency anemia patients before and after treatment. They showed 
that in anemic patients the mean baseline HbA1c level is lower and it 
increased after treating with iron. But the study group belonged to a lower 
socio economic level. The cause of iron deficiency anemia in those 
patients is nutritional deficiency rather than malabsorption and bleeding 
and that could have affected the results.
(56)
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          Brooks et al carried out a study in individuals with iron deficiency 
anemia. They estimated HbA1c values before and after treating them with 
iron. And they noted that the mean concentration of HbA1c was elevated 
in iron deficiency anemia patients and it decreased after treatment. There 
was a postulation that the quarternary structure of the hemoglobin may be 
altered in iron deficiency anemia resulting in a higher rate of 
glycosylation of the β globin chain.(28)  
          Sluiter et al postulated that the glycosylation of hemoglobin is an 
irreversible process and the concentration of HbA1c in a red blood cell 
increases with cell age. The levels of HbA1c should be normal in 
individuals with normal glycemic status and normal red blood cell life 
span. In the event of chronic iron deficiency anemia, red blood cell 
production will decrease leading to anemia and a longer span for the red 
blood cells present in the circulation. After treating with iron, HbA1c 
levels will decrease which is attributable to the phenomenon shorter life 
span of red blood cells. 
(40) 
          Mitchell et al calculated the absolute amount of HbA1c using the 
mean cell hemoglobin in each red blood cell before and after 6 weeks of 
iron therapy. The HbA1c levels were 1.9pg and 1.95pg respectively, 
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which conveyed that there was no significant difference of iron therapy 
on HbA1c.
(41) 
         It was postulated that the differences in HbA1c values seen in 
previous studies could have been a result of the post translational 
alterations of hemoglobin rather than the glycosylation. In cation 
exchange chromatography assay methods the modified hemoglobin 
would elute with the HbA1c and affect the readings. But that 
modification would not affect the readings in affinity gel assays because 
those assays are based on the binding between the glucose molecule on 
the β chain and the gel alone.(42) 
Some studies showed that the supplementation with iron and 
vitamin B12 resulted in significant decrease in HbA1c values and altered 
red blood cell indices. It was said that in iron deficiency anemia the life 
span of red blood cell is normal but decreased in vitamin B12 deficiency 
anemia. The lower HbA1c values seen after treatment could be the result 
of increased bone marrow production of new red blood cells and release 
of immature cells.
(43) 
A study done in Pediatric patients with type 1 DM, with one third 
of them having iron deficiency anemia, showed an inverse relationship 
between HbA1c and hemoglobin levels. In diabetic patients with iron 
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deficiency anemia, higher HbA1c levels were found independent of 
glycemic control. HbA1c levels decreased with iron supplementation. 
This could be a result of young red blood cells that appear after iron 
supplementation which lead to a dilution effect and lowering of HbA1c 
values. They postulated that there was no correlation between other red 
cell indices and HbA1c. Rather than iron concentration, structural or 
affinity changes in hemoglobin are reflected in changes of HbA1c 
levels.
(44) 
Coban et al. carried out a study that compared the HbA1c levels in 
non patients with iron deficiency anemia to normal control groups. They 
observed that the mean HbA1c level in patients with iron deficiency 
anemia is higher than the control group. And after a 3 month course of 
iron therapy, the mean HbA1c level significantly decreased.
(46)
  
          Aslan et al. conducted a study on glycosylated hemoglobin for its 
potential use as a marker to differentiate thalassemia and iron deficiency 
anemia. They measured HbA1c levels in β thalassemia, iron deficiency 
anemia patients and normal healthy controls. The calculated mean HbA1c 
level was lower in β thalassemia minor compared to iron deficiency 
anemia patients. There was no difference noted between iron deficiency 
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anemia patients and control groups. They postulated that it could be due 
to normal red blood cell survival rate in iron deficiency anemia.
(47)
  
          Koga et al. studied about the link of menopause to iron deficiency 
anemia and HbA1c. In premenopausal women they evaluated the red 
blood cell indices and HbA1c, which showed that the RBC count is 
positively associated with glycosylated hemoglobin. In contrast 
hemoglobin, MCV and MCH is negatively associated with glycosylated 
hemoglobin. But none of the indices could be linked to HbA1c in the 
postmenopausal group.
(48) 
          Harvey et al. carried out a study, which showed that the MCV and 
MCH indices are affected earlier than the total Hb and RBC count. Blood 
loss during menses can cause iron deficiency anemia with low MCV and 
MCH values in premenopausal women. It was postulated that it could be 
the cause for the elevated levels of HbA1c observed in them.
(49) 
          In 2010, Koga et al. carried out a study in premenopausal women to 
find out the relation between the indices of iron metabolism and HbA1c. 
According to this study there was an inverse association between the H 
bA1c and the serum iron, serum transferrin saturation and serum ferritin. 
Higher HbA1c levels were observed in iron deficiency anemia group than 
in the normal iron state group. This study concluded that in 
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premenopausal women the regardless of anemia, iron deficiency 
increases HbA1c levels.
(50)
  
          Hashimoto et al. tried to find a correlation between glycemia and 
HbA1c in pregnant women. Most women in late pregnancy already have 
iron deficiency anemia. They conducted two studies in pregnant women 
included non diabetic and later diabetic pregnant women not 
supplemented with iron using the indices of erythrocyte and iron 
metabolism. In late pregnancy, HbA1c levels were significantly elevated 
in both the studies. There was found to be a negative correlation between 
HbA1c levels and mean corpuscular hemoglobin, serum transferrin and 
serum iron saturation. From this, they postulated that the increased 
HbA1c levels seen in late pregnancy was because of the presence of iron 
deficiency anemia at this stage.
(51) 
         In 2012, Rafat et al. tried to analyze the influence of iron indices 
over HbA1c in pregnant women with iron deficiency anemia. They found 
a significant correlation between the indices of red blood cell and iron 
metabolism and HbA1c. The study indicated that in women with iron 
deficiency anemia HbA1c levels were elevated and it decreased after the 
iron supplementation.
(52)
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          Kim et al. stated that iron deficiency anemia increased the HbA1c, 
from the observations of iron deficiency and HbA1c in non diabetic 
adults in the National Health and Nutrition Examination Survey 
(NHANES). This effect was seen at the lower spectrum of HbA1c levels 
i.e. between 5.5 – 6.0% and below 5.5%.(32) 
          Observations on iron deficiency anemia and normal iron states, 
using cross sectional data on HbA1c levels from the NHANES study, 
stated that there was a significant positive correlation between HbA1c 
and hemoglobin among adults with and without iron deficiency.
(53)
 
Sharifi et al. concluded that there was a negative correlation between 
HbA1c and erythrocyte hemoglobin, which supported the postulation that 
iron deficiency increases glycosylation of hemoglobin
(54)
.  
          Ng JM et al. conducted a study in type 2 diabetic patients with 
chronic kidney disease who are treated with parenteral iron and/or ESA 
(Erythrocyte Stimulating Agents). They observed a statistically 
significant decrease in HbA1c levels after treatment, regardless of 
glycemic control
(55)
.   
          In 2012 Hardikar et al. conducted a study in Indians, which 
analysed the effect of glycemia and other non glycemic parameters over 
HbA1c levels. They postulated that if HbA1c is used to diagnose 
prediabetes and diabetes in iron deficiency anemia patients, it will result 
in false high prevalence.
(57)
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THEORIES ON EFFECT OF IDA OVER HBA1C LEVELS 
I. It was postulated that there may be an alteration in the quarternary 
structure of the hemoglobin molecule in iron deficiency anemia. 
That alteration will result in increased level of glycosylation of the 
β-globin chain during iron deficient state. 
II. A) Life span of the red blood cells present in the circulation may be 
prolonged during anemic state resulting in higher HbA1c levels in 
iron deficiency anemia patients. 
III. B) After treatment with iron there will be increased bone marrow 
red cell production and release of new immature red cells resulting 
in lower HbA1c levels.  
IV. There was a postulation that there is a balance between hemoglobin           
concentration and HbA1c levels. So, if the serum glucose remained 
constant a decrease in hemoglobin concentration could cause an 
increase in the glycated fraction.   
V. Use of different assay methods 
  
MATERIALS
AND
METHODOLOGY
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MATERIALS AND METHODS 
Study Title 
“A STUDY ON INFLUENCE OF IRON DEFICIENCY 
ANAEMIA OVER HBA1C LEVELS’’ 
Aims and Objectives 
Primary objective 
To study the levels of HbA1c in iron deficiency anemia patients  
Secondary objective  
To study the changes in HbA1c level with the correction of iron 
deficiency anemia 
Study centre 
DEPARTMENT OF GENERAL MEDICINE, 
          ESIC MEDICAL COLLEGE & PGIMSR, 
          K.K. NAGAR, CHENNAI – 78  
Study design 
PROSPECTIVE INTERVENTIONAL STUDY 
Study Period 
           18 months 
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Inclusion criteria 
• All consented Iron deficiency anemia patients  attending  Medical 
OPD and  medical wards  in our hospital 
• Age between 18 to 60 years 
Exclusion criteria 
• Age <18 years  or  >60 years 
• Patients with diabetes/IFG/IGT 
• Patients with chronic renal failure/ liver disease 
• Patients with haemolytic anaemia 
• Pregnancy 
• Chronic alcoholism 
• Known case of malignancy 
Study population 
        All patients coming to the department of general medicine, ESIC 
medical college & PGIMSR, fulfilling the inclusion and exclusion criteria 
were enrolled in the study. An informed written consent was obtained 
from the patients.  
Data collection 
       A detailed history was recorded along with complete clinical 
examination as in the proforma. Provisional diagnosis was made and this 
was subsequently revised after completion of the investigations. 
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Laboratory investigations 
     Samples were collected from all the participants to estimate 
complete blood count, blood urea, serum creatinine, serum electrolytes, 
blood sugar- FBS/PPBS/GTT, urine R/E, HbA1c level, anemia profile 
including serum ferritin, vitamin B12 and folic acid levels, based on 
standard tests available in our hospital. In addition, ECG, chest xray and 
ultrasonogram abdomen were done in necessary cases. The final data was 
entered onto Microsoft excel sheet 2007 version. 
Study protocol 
       Patients with iron deficiency anemia based on WHO criteria cut off 
point and age, sex matched control patients were assigned for study. 
History, clinical assessment and investigations including serum ferritin, 
HbA1c were done. 
NORMAL LEVELS 
1.  Serum iron  :  50-150mic/dl 
2.  Serum ferritin  : 50-200mic/l                                 
3.  TIBC    :  300-360mic/dl 
4.  Transferrin saturation :  25-50%  
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HAEMOGLOBIN LEVELS TO DIAGNOSE ANAEMIA 
(g/dl)(WHO) 
MEN <13g/dl 
WOMEN <12g/dl 
 
Patients coming to OPD and in wards 
 
history 
clinical assessment 
investigations including anaemia profile 
patients with iron deficiency anemia      age, sex matched controls 
                 
                   HbA1c levels                                       HbA1c levels                      
             
       anaemia correction with iron supplementation      
  
         follow up HbA1c levels after 3 months 
                 
                   conclusion 
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Collaborating Departments 
Department of General Medicine,  Department of Biochemistry 
and Department of Pathology 
Ethical committee  
clearance   :  obtained 
Consent   :  Individual written and informed consent 
Conflict of interest :  Nil 
Sponsorship  :  No sponsorship 
STATISTICAL ANALYSIS 
The clinical parameters were compared and analyzed using Pearson 
chi square method. The diagnostic accuracy of all the parameters was 
then compared and interpreted with reference to clinical data. 
          In the present study, the statistical methods for quantitative data, 
descriptive statistics was presented by N, Mean, Standard Deviation and 
Range. For qualitative data, frequency count, N and percentage were put 
in a tabular manner. 
          To analyze the data, appropriate statistical tests were applied. The 
significance of difference between means in two groups was calculated 
using student t test and the significance of difference in proportions using 
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chi-square test. 2 x 2 tables were constructed for each variable and chi 
square value for degree of freedom calculated. 
          All the statistical analysis has been done by using statistical 
software SPSS (version 22). Other data, displayed by various tables and 
charts, by using Microsoft excel (windows 7). 
*  - Significant - p < 0.05 
**  - Very significant - p <0.01 
***  - Highly significant - p < 0.001 
  
RESULTS
AND
ANALYSIS
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OBSERVATION AND RESULTS 
Table 5.1 AGE DISTRIBUTION 
AGE (years) CONTROL GROUP N (%) STUDY GROUP N (%) 
≤20 12(10) 5(4.2) 
21-30 51(42.5) 40(33.3) 
31-40 28(23.3) 41(34.2) 
>40 29(24.2) 34(28.3) 
TOTAL 120(100) 120(100) 
Mean 32.06 34.067 
SD 8.34 8.398 
P value 0.064 Not Significant 
 
Interpretation 
Mean age (±SD): in control group was 32.1 (8.34) and in study 
group was 34.1 (8.398).P value was 0.064 which is not significant i.e. the 
age distribution among the control and study group were equal.  
 
Figure 5.1: AGE DISTRIBUTION 
Comments 
            About 67% of study subjects were in the age group of 21-40 years 
while 28% were aged 41-60 years. Minimum age: 19 years, maximum 
age: 49 years. 
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Table 5.2 SEX DISTRIBUTION 
SEX 
CONTROL GROUP 
N (%) 
STUDY GROUP 
N (%) 
MALE 56(46.7) 38(31.7) 
FEMALE 64(53.3) 82(68.3) 
TOTAL 120 120 
P value 0.146 Not Significant 
 
Interpretation 
            Majority of the study subjects were females (68.3%) while the 
remaining 31.7% were males. It confirms the fact that iron deficiency 
anemia is more common in females. P value was 0.146 which is not 
significant i.e. sex distribution among the control group and study group 
were equal.   
 
Figure 5.2: SEX DISTRIBUTION 
  
SEX DISTRIBUTION 
MALE
FEMALE
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Table 5.3 FBS DISTRIBUTION 
FBS mg/dl CONTROL GROUP N (%) STUDY GROUP N (%) 
≤80 11(9.2) 10(8.3) 
81-90 66(55) 68(56.7) 
91-110 43(35.8) 42(35) 
N 120 120 
Mean 88.508 88.525 
SD 5.312 5.231 
P value 0.98  not significant 
 
     
  
Figure 5.3: FBS DISTRIBUTION 
Interpretation: 
            Mean (±SD): in control group was 88.508(5.312) and in study 
group was 88.525(5.231). P value was 0.98 which is not significant i.e. 
FBS distribution among the control and study group were same.  
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Table 5.4 PPBS DISTRIBUTION 
PPBS 
mg/dl 
CONTROL GROUP N (%) STUDY GROUP N (%) 
≤110 48(40) 57(47.5) 
111-120 29(24.1) 21(17.5) 
121-130 32(26.7) 32(26.7) 
131-140 11(9.2) 10(8.3) 
N 120 120 
Mean 114.65 112.352 
SD 12.522 13.725 
P value 0.185  Not significant 
  
 
Figure 5.4: PPBS DISTRIBUTION 
Interpretation 
Mean (±SD): in control group was 114.65(12.522) and in study 
group was 112.352(13.725). P value was 0.185 which is not significant 
i.e. PPBS distribution among the control and study group were same.  
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Table 5.5 DISTRIBUTION OF HEMOGLOBIN  
IN CONTROL GROUP 
HB (g/dl) CONTROL GROUP N (%) 
12-13 23(19.2) 
>13 97(80.8) 
N 120 
Mean 13.408 
SD 0.354 
 
Interpretation 
Mean (±SD): 13.408(0.354) gm/dl, minimum: 12.8gm/dl, 
maximum: 14gm/dl. 
 
Figure 5.5: DISTRIBUTION OF HEMOGLOBIN IN CONTROL 
GROUP 
Comments 
About 80.8% of control subjects had Hb level more than 13gm/dl 
while 19.2% had Hb level between 12-13gm/dl. 
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Table 5.6 DISTRIBUTION OF HEMOGLOBIN IN STUDY GROUP 
PRE-CORRECTION 
 
HB (g/dl) STUDY GROUP PRE N (%) 
<8 103(85.8) 
8.0-8.9 17(14.2) 
≥9 0(0) 
N 120 
Mean 6.778 
SD 1.085 
 
Interpretation 
Mean (±SD): 6.778(1.085) gm/dl, minimum: 2.9gm/dl, maximum: 
8.3gm/dl. 
 
Figure 5.6: DISTRIBUTION OF HEMOGLOBIN IN  
STUDY GROUP PRE-CORRECTION 
Comments 
About 85.8% of study subjects had Hb level less than 8gm/dl while 
14.2% had Hb level between 8.0-8.9gm/dl. 
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Table 5.7 DISTRIBUTION OF HEMOGLOBIN IN STUDY GROUP 
POST-CORRECTION 
HB (g/dl) STUDY GROUP POST N(%) 
12-13 82(68.3) 
>13 38(31.7) 
N 120 
Mean 12.659 
SD 0.446 
 
Interpretation 
Mean (±SD): 12.659(0.446) gm/dl, minimum: 12gm/dl, maximum: 
13.5gm/dl. 
 
Figure 5.7: DISTRIBUTION OF HEMOGLOBIN IN STUDY 
GROUP POST-CORRECTION 
Comments 
After correction of anemia, about 68.3% of study subjects had Hb 
level between 12-13gm/dl, while 31.7% had Hb level more than 13gm/dl. 
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Table 5.8 DISTRIBUTION OF HEMOGLOBIN BETWEEN 
CONTROL AND STUDY GROUP PRE-CORRECTION 
HB (g/dl) CONTROL GROUP STUDY GROUP PRE 
≤13 23 120 
>13 97 0 
N 120 120 
Mean 13.408 6.778 
SD 0.354 1.085 
P value <0.001  Significant 
 
  
Figure 5.8: DISTRIBUTION OF HEMOGLOBIN BETWEEN 
CONTROL AND STUDY GROUP PRE-CORRECTION 
Interpretation: 
             P value was less than 0.001 which is highly significant i.e. mean 
hemoglobin level in study group was significantly lower than the control 
group as expected.  
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Table 5.9 DISTRIBUTION OF HEMOGLOBIN IN STUDY GROUP 
PRE AND POST CORRECTION 
HB (g/dl) STUDY GROUP PRE STUDY GROUP POST 
≤13 120 82 
>13 0 38 
N 120 120 
Mean 6.778 12.659 
SD 1.085 0.446 
P value <0.001  Significant 
 
 
Figure 5.9: DISTRIBUTION OF HEMOGLOBIN IN STUDY 
GROUP PRE AND POST CORRECTION 
Interpretation: 
            P value was less than 0.001 which is highly significant i.e. mean 
hemoglobin level had increased significantly in study subjects after iron 
treatment   as expected. 
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Table 5.10 DISTRIBUTION OF MCV 
MCV (fl) 
CONTROL 
GROUP N(%) 
STUDY 
GROUP PRE 
N(%) 
STUDY 
GROUP POST 
N(%) 
<80 0(0) 120(100) 0(0) 
80-90 45(37.5) 0(0) 44(36.7) 
91-100 75(62.5) 0(0) 76(63.3) 
N 120 120 120 
Mean 91.316 64.46 91.349 
SD 2.851 6.674 2.81 
P value <0.001  Significant <0.001  Significant 
 
 
Figure 5.10: DISTRIBUTION OF MCV 
Interpretation: 
            P value between control group and study group before anemia 
correction was less than 0.001 which is highly significant. It conveys that 
MCV was significantly lower in anemia group. 
            P value between study group pre and post correction was less than 
0.001 which is highly significant. It indicates that MCV improved after 
iron treatment as expected.  
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Table 5.11 DISTRIBUTION OF MCH 
MCH 
(pg/cell) 
CONTROL 
GROUP N(%) 
STUDY 
GROUP  
PRE N (%) 
STUDY GROUP 
POST N(%) 
<26 0(0) 119(99.2) 0(0) 
26-28 50(41.7) 0(0) 49(40.8) 
>28 70(58.3) 1(0.8) 71(59.2) 
N 120 120 120 
Mean 28.277 19.615 28.283 
SD 0.836 3.018 0.833 
P value <0.001  Significant <0.001  Significant 
 
 
Figure 5.11: DISTRIBUTION OF MCH 
Interpretation: 
P value between control group and study group before anemia 
correction was less than 0.001 which is highly significant. It conveys that 
MCH was significantly lower in anemia group. 
          P value between study group pre and post correction was less than 
0.001 which is highly significant. It indicates that MCH improved after 
iron treatment as expected.  
0
20
40
60
80
100
120
<26 26-28 >28
N
o
.o
f 
P
eo
p
le
 
MCH (pg/cell) 
CONTROL GROUP
STUDY GROUP PRE
STUDY GROUP POST
 
 
73 
Table 5.12 DISTRIBUTION OF SERUM IRON 
SERUM IRON 
(mic gm/dl) 
CONTROL 
GROUP N(%) 
STUDY 
GROUP PRE 
N(%) 
STUDY 
GROUP POST 
N(%) 
<30 0(0) 120(100) 0(0) 
31-60 0(0) 0(0) 0(0) 
61-90 3(2.5) 0(0) 4(3.3) 
91-120 53(44.2) 0(0) 54(45) 
>120 64(53.3) 0(0) 62(51.7) 
N 120 120 120 
Mean 117.167 21.257 117.147 
SD 13.091 4.688 12.661 
P value <0.001  Significant <0.001  Significant 
 
 
Figure 5.12: DISTRIBUTION OF SERUM IRON 
Interpretation: 
P value between control group and study group before anemia 
correction was less than 0.001 which is highly significant. It conveys that 
serum iron was significantly lower in anemia group. 
P value between study group pre and post correction was less than 
0.001 which is highly significant. It indicates that serum iron improved 
after iron treatment as expected.  
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Table 5.13 DISTRIBUTION OF SERUM FERRITIN 
SERUM 
FERRITIN (g/L) 
CONTROL 
GROUP N(%) 
STUDY GROUP 
PRE N(%) 
STUDY GROUP 
POST N(%) 
<15 0(0) 120(100) 0(0) 
16-50 0(0) 0(0) 0(0) 
51-150 0(0) 0(0) 0(0) 
151-300 119(99.2) 0(0) 120(100) 
>300 1(0.8) 0(0) 0(0) 
N 120 120 120 
Mean 232.264 6.871 237.239 
SD 28.394 1.5 25.267 
P value <0.001  Significant <0.001  Significant 
 
 
Figure 5.13: DISTRIBUTION OF SERUM FERRITIN 
Interpretation: 
P value between control group and study group before anemia 
correction was less than 0.001 which is highly significant. It conveys that 
serum ferritin was significantly lower in anemia group. 
          P value between study group pre and post correction was less than 
0.001 which is highly significant. It indicates that serum ferritin improved 
after iron treatment as expected.   
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Table 5.14 DISTRIBUTION OF HBA1C BETWEEN CONTROL 
AND STUDY GROUP PRE-CORRECTION 
HBA1C 
(%) 
CONTROL GROUP 
N(%) 
STUDY GROUP 
PRE N(%) 
≤5 10(8.3) 104(86.7) 
5.1-5.5 66(55) 16(13.3) 
5.6-6.0 42(35) 0(0) 
6.1-6.5 2(1.7) 0(0) 
>6.5 0(0) 0(0) 
Mean 5.446 4.619 
SD 0.281 0.308 
P value <0.001  Significant 
 
 
Figure 5.14: DISTRIBUTION OF HBA1C BETWEEN CONTROL 
AND STUDY GROUP PRE-CORRECTION 
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Interpretation 
Mean HbA1c of iron deficiency anemia patients (4.619 ± 0.308) 
was significantly lower than control population (5.446 ± 0.281).    
About 55% of control subjects had HbA1c level between 5.1-5.5% 
while 35% had HbA1c level between 5.6-6.0%.             
About 86.7% of study subjects had HbA1c level between ≤5% 
while 13.3% had HbA1c level between 5.1-5.5%.           
P value of HbA1c distribution between control group and study 
group pre-correction was less than 0.001 which is highly significant. It 
reveals that HbA1c was lower in anemia group.  
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Table 5.15 DISTRIBUTION OF HBA1C IN STUDY GROUP PRE 
AND POST CORRECTION 
HBA1C 
(%) 
STUDY GROUP 
PRE N(%) 
STUDY GROUP 
POST N(%) 
≤5 104(86.7) 0(0) 
5.1-5.5 16(13.3) 32(26.7) 
5.6-6.0 0(0) 55(45.8) 
6.1-6.5 0(0) 33(27.5) 
>6.5 0(0) 0(0) 
Mean 4.619 5.816 
SD 0.308 0.323 
P value <0.001  Significant 
 
 
Figure 5.15 DISTRIBUTION OF HBA1C IN STUDY GROUP PRE 
AND POST CORRECTION 
Interpretation:  
The mean HbA1c level in the study group increased from 
4.619(±0.308) % to 5.816(±0.323)% after correction of anemia 
After correction of anemia about 45.8% of study subjects had 
HbA1c level between 5.6-6.0% while 27.5% had HbA1c level between 
6.1-6.5%.  P value of HbA1c in study group pre and post correction was 
less than 0.001 which is highly significant. It indicates that HbA1c 
increased after anemia correction.  
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Table 5.16 Mean Difference result in pre & post correction for  
Hb & HbA1c values 
Parameters Mean Difference 
Hb (gm%) 5.88*** 
HbA1c (%) 1.20*** 
 *** Highly Significant (P=0.0001) 
 
Figure 5.16: Mean Difference result in pre & post correction  
for Hb & HbA1c values 
 
Interpretation 
           In this study HbA1c significantly increased after correction of 
anemia.     
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Table 5.17 Pre correction result for correlation: 
Hb – Pre correction 
HbA1C- pre 
correction 
Interpretation 
Pearson Correlation 
coefficient r 
0.26 
Positive, poor 
correlation 
P value 0.005** very significant 
Sample size (n) 120 
  
Interpretation 
  In this study group, pre correction Hb & HbA1C showed positive, 
poor correlation (r = 0.26) which was statistically very significant  
(p= 0.005) 
 
Figure 5.17: Correlation between Hb & HbA1C in study group 
before correction 
Comments 
In this scatter diagram, the trend line shows positive, poor and 
statistically significant correlation. For this line, Regression equation 
obtained, Y (HbA1C) = 0.072 (X = Hb) + 4.0124. That is, If we put the 
value of Hb (X) = 10gm %, the predicted HbA1C would be 4.73%. And 
for Hb = 12 gm %, the predicted HbA1C would be 4.88%. i.e. there was 
increase of 0.15% HbA1C level for each 2gm of Hb level. 
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Table 5.18 Post correction result for correlation 
Hb -post correction 
HbA1c- post 
correction 
Interpretation 
Pearson Correlation 
coefficient r 
-0.15 
Negative, poor 
correlation 
P value 0.111 Not significant 
Sample size 120 
  
Interpretation 
In this study group, post correction Hb & HbA1C showed negative, 
poor correlation (r = -0.15) which was statistically not significant  
(p= 0.111) 
           
 
Figure 5.18: Correlation between Hb & HbA1c in study group after 
anemia correction 
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In this scatter diagram, the trend line shows negative, poor and 
statistically not significant correlation. For this line, Regression equation 
obtained, Y (HbA1C) = - 0.105 (X = Hb) + 7.156. That is, If we put the 
value of Hb (X) = 10gm %, the predicted HbA1C would be 6.11%. And 
for Hb = 12 gm %, the predicted HbA1C would be 5.9%. i.e. there was 
decrease of 0.21% HbA1C level for each 2gm  of Hb level. 
Inference 
Sample size may not be enough to prove post correction 
correlation. 
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DISCUSSION 
Iron deficiency is the commonest malnutrition. It is a major public 
health problem in both developing and developed countries. 
          Iron deficiency contributes to 50 percentage of anemia worldwide. 
Annually, about 8,41,000 deaths were attributed to iron deficiency 
anemia. Parts of Asia and Africa are affected more. These countries bear 
approximately 71 percentage of the global mortality burden.  
         In India, about 50% of anemia is attributed to iron deficiency. 
Children and women are the most vulnerable population. The factors 
contributing to iron deficiency anemia varies in different population.  
          Physiologically, HbA undergoes glycosylation in a slow and non 
enzymatic manner. The degree of glycosylation depends on the 
concentration of glucose. HbA1c is the predominant form of glycated 
hemoglobin. Glucose gets attached to the NH2 group in the terminal 
valine of the β-globin chains irreversibly.  
          Glycosylation process occurs throughout the life span (120 days) of 
red cells. Hence the measured glycohemoglobin levels reflect the 
glycemic status of the preceding 3 months.   
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          HbA1c levels can be affected by multiple factors other than the 
plasma glucose level. Several conditions can result in falsely lower or 
higher values. Hemolytic anemia, hemoglobinopathies, uremia and 
chronic blood loss influence the HbA1c assays.  
           So far HbA1c has been used as a valuable tool in monitoring the 
glycemic control in diabetics. Recently American Diabetic Association 
and International Expert Committee recommended HbA1c for diagnosing 
diabetes. HbA1c level of 6.5% has been proposed as a diagnostic cut off 
point.  
           There were multiple studies investigating the relationship between 
iron deficiency anemia and HbA1c. But the results were inconsistent.  
           Our study aims to measure the HbA1c levels in iron deficiency 
anemia patients and to identify the changes in HbA1c levels after 
correcting the iron deficiency anemia.     
Age distribution of the study population 
            In this study about 120 patients were allotted to the study group. 
The same number of age and sex matched controls were taken. The mean 
age group of the study population was 34.1±8.4 years. The minimum age 
was 19 years and the maximum was 49 years.  About 67% of the study 
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subjects were in the age group of 21-40 years while 28% were aged 41-60 
years. Thus in our study, the prevalence of iron deficiency anemia is more 
common in 2
nd
 to 4
th
 decade of life.  
Sex distribution of the study population: 
            In this study, out of 120 patients 68.3% were females and 31.7% 
were males.  It confirms the fact that women are more vulnerable to iron 
deficiency than men. The age and gender distribution of population in 
both the study and control groups were equal and comparable.  
Hemoglobin distribution of the study population: 
           The mean hemoglobin of the study population was 6.8(±1.1)gm/dl. 
About 85.8 % of the study population had severe anemia i.e. less than 8 
gm/dl. The minimum hemoglobin observed in the study population was 
2.9 gm/dl and the maximum was 8.3 gm/dl.  
          The p value of unpaired t test between the study group hemoglobin 
and control group was less than 0.001 which is highly significant. It 
indicates that mean hemoglobin level in study group was significantly 
lower than the control group as expected.  
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         The mean hemoglobin level in the study group increased from 
6.8(±1.1)gm/dl to 12.7(±0.4)gm/dl after correction of anemia with iron. 
The minimum hemoglobin observed in the study population after iron 
treatment was 12gm/dl and the maximum was 13.5gm/dl. 
          The p value of paired t test in the study group hemoglobin before 
and after iron treatment was less than 0.001 which is highly significant. It 
indicates that mean hemoglobin level had increased significantly in study 
subjects after iron treatment   as expected. 
Red cell indices of the study population: 
          The mean MCV and MCH of the control and study group were 
91.316(±2.851), 28.277(±0.836) and 64.46(±6.674), 19.615(±3.018) 
respectively. This shows that MCV, MCH were lower in the study group 
compared to the control group. The observed difference was statistically 
significant (p<0.001).  
           The mean MCV and MCH of the study group after iron treatment 
were 91.349(±2.81) and 28.283(±0.833) respectively. That was a 
statistically significant improvement.  
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Iron status of the study population 
The mean serum iron and ferritin levels of the control and study 
group were 117.167(±13.091), 232.264(±28.394) and 21.257(±4.688), 
6.871(±1.5) respectively. This shows that serum iron and ferritin levels 
were lower in the study group compared to the control group. The 
observed difference was statistically significant (p<0.001).  
          The mean serum iron and ferritin levels of the study group after 
iron treatment were 117.147(±12.661) and 237.239(±25.267) 
respectively. That was a statistically significant improvement.  
HbA1c level of the study population 
           The mean HbA1c of the study population was 4.619(±0.308) %. 
About 86.7% of study subjects had HbA1c level ≤5% while 13.3% had 
HbA1c level between 5.1-5.5%. The mean HbA1c of the control group 
was 5.446(±0.281) %.        
The p value of unpaired t test between the study group HbA1c and 
control group was less than 0.001 which is highly significant. It indicates 
that mean HbA1c level in study group was significantly lower than the 
control group.  
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          The mean HbA1c level in the study group increased from 
4.619(±0.308) % to 5.816(±0.323)% after correction of anemia with iron. 
After correction of anemia about 45.8% of study subjects had HbA1c 
level between 5.6-6.0% while 27.5% had HbA1c level between 6.1-6.5%.  
           The p value of paired t test in the study group HbA1c before and 
after anemia correction was less than 0.001 which is highly significant. It 
indicates that mean HbA1c level had increased significantly in study 
subjects after anemia correction. 
Correlation between Hb & HbA1C 
            In this study group, pre correction Hb & HbA1C showed positive, 
poor correlation (r = 0.26) which was statistically very significant (p= 
0.005). That is, when the hemoglobin decreases the HbA1c will also 
decrease and vice versa.   
           And post correction Hb & HbA1C showed negative, poor 
correlation (r = -0.15) which was statistically not significant (p= 0.111). 
That is, when the hemoglobin increases the HbA1c will decrease and vice 
versa, which is not significant statistically.  
           Similar to this study, in 2014 a study was conducted by Vishal 
Kalasker et al
(59)
 on the effect of iron deficiency anemia on glycosylated 
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hemoglobin levels in non diabetic indian adults. They postulated that Hb 
concentrations are positively corrected with HbA1c concentration and 
that HbA1c concentration tended to be lower in the presence of iron 
deficiency anemia. But they concluded that iron deficiency anemia is 
unlikely to be a major concern in diagnosing diabetes using concentration 
of HbA1c according to the American Diabetes Association (ADA) 
guideline. 
            In contrast to our study, a study done by Alap L. Christy et al
(37)
  
concluded that iron deficiency anemia elevates HbA1c levels in diabetic 
individuals with controlled plasma glucose levels. They postulated that 
iron deficiency anemia has a positive correlation with increased HbA1c 
levels.  
          A study done by Catherine Kim et al
(32)
 concluded that iron 
deficiency shifted the HbA1c slightly upwards independent of fasting 
glucose level. 
           In non GDM mothers, Sasekala et al
(58)
 conducted a descriptive 
cross sectional study. They showed that in anemic non GDM mothers the 
HbA1c levels are higher. So they advised to be cautious in interpreting 
the HbA1c and plasma sugar levels.  
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           Alap L. Christy et al
(38)
 conducted a study to evaluate the 
relationship between HbA1c and anemia in hypothyroid patients. They 
concluded that Nondiabetic hypothyroid individuals with anemia shows 
elevate A1C levels in prediabetes range. Hence care should be exercised 
while using HbA1C as a diagnostic tool for diabetes in such patients.
 
            Study done by Van Heyningen et al
(42)
 found out that there was no 
significant influence of iron deficiency anemia over HbA1c 
concentrations. They suggested that differences observed in previous 
studies could be due to the various laboratory methods used in estimating 
the HbA1c. Hansen et al also observed similar results. Contradicting the 
conclusion of Van Heyningen et al, Rai et al conducted a study using 
various assay methods to estimate HbA1c and found no significant 
alterations in HbA1c levels measured by those methods. 
            El-Agouza et al
(45)
 reported that iron deficiency anemia patients 
had higher HbA1c levels and it decreased after treatment. They believed 
that there was a balance between hemoglobin concentration and HbA1c 
level. That is if the plasma glucose was maintained, the lower 
hemoglobin concentration would lead to rise in HbA1c levels.  
           In our study mean HbA1c of iron deficiency anemia patients 
(4.619 ± 0.308) was significantly lower than control population  
(5.446 ± 0.281) and it increased (5.816 ± 0.323%) significantly after iron 
treatment. 
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SUMMARY 
            Iron deficiency anemia is the most common nutritional anemia. It 
contributes to more than half of the global anemia burden. HbA1c was 
used to assess the glycemic control. But recent studies have 
recommended HbA1c to diagnose diabetes. HbA1c levels can be affected 
by multiple non glycemic parameters. This study was conducted to study 
the influence of iron deficiency anemia over HbA1c levels and to study 
the changes in HbA1c levels after correcting the iron deficiency anemia. 
           Our study confirmed that iron deficiency anemia was highly 
prevalent among women during the second to fourth decades of life. 
           Mean HbA1c of patients with iron deficiency anemia (4.619 ± 
0.308) was lower, compared to healthy control group (5.446 ± 0.281)  
with p value less than 0.001(significant).In iron deficiency anemia 
patients mean HbA1c increased from 4.619 ± 0.308 % to 5.816 ± 0.323% 
after iron treatment with p value less than 0.001 which is statistically 
significant. 
           Among patients with iron deficiency anemia, hemoglobin and 
HbA1c showed positive poor correlation (r = 0.26) which was statistically 
very significant (p= 0.005). After anemia correction hemoglobin and 
HbA1c showed negative, poor correlation (r = -0.15) which was 
statistically insignificant (p= 0.111). 
CONCLUSION
 
 
91 
CONCLUSION 
 The prevalence of iron deficiency anemia is more common in 
females during the second to fourth decades of life. 
 HbA1c was lower in patients with iron deficiency anemia 
compared to healthy control group. 
 After correction of anemia, HbA1c level increased significantly in 
iron deficiency anemia patients. 
 Hemoglobin and HbA1c showed statistically significant positive 
correlation in patients with iron deficiency anemia. 
 After correction of anemia Hemoglobin and HbA1c showed 
statistically insignificant negative correlation.  
 Longer period of study and a larger sample size may be required to 
show a statistically significant positive correlation. 
 Iron deficiency anemia has to be kept in mind before using the 
HbA1c to diagnose diabetes. 
 
 
LIMITATIONS
 
 
92 
LIMITATIONS 
 The sample size of the study was small. 
 The study period was short. 
 The study should be done at the community level to prove a 
statistically significant correlation.  
 
 
 
 
 
 
 
 
 
  
FUTURE
PROSPECTIVES
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FUTURE PROSPECTIVES 
 Large scale trials over longer durations may give accurate 
information about the influence of iron deficiency anemia over 
HbA1c levels. This will increase the reliability of HbA1c in 
diagnosing diabetes.  
 Further studies can be done in other markers of glycemic control 
like glycated albumin and fructosamine in iron deficiency anemia 
patients to assess their usefulness.   
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ANNEXURES
 
 
ANNEXURES - I 
PROFORMA 
Name:                     Address: 
Age:                                                  Occupation: 
Sex:                                                   Socio economic status: 
IP NO:                                              Education: 
DOA:      DOD:                   Ward/unit:                              
PRESENTING COMPLAINTS: 
DETAILED HISTORY: 
EXAMINATION:                                      
 General examination 
 Vital signs 
Pulse:            Blood  pressure: 
Respiratory rate:     Temperature:                          
Body mass index (BMI): 
 Systemic examinations 
CVS  :        RS   : 
          Abdomen :        CNS :  
 
 
INVESTIGATIONS 
 COMPLETE HEMOGRAM 
          Hb (g/dL) 
          TC   (cells/cu.mm) 
          DC 
          RBC (millions/cu.mm) 
          Platelets (Lakhs/cu.mm) 
          PCV 
 ANAEMIA   PROFILE 
           Peripheral smear 
           Serum Iron 
           Serum ferritin 
           TIBC 
           Transferrin saturation 
           Vit B 12 and folic acid level 
 HBA1C 
 URINE ANALYSIS 
          Albumin 
          Sugar 
          Deposits 
 BLOOD SUGAR (MG/DL)—FBS/PPBS/GTT 
 LIVER FUNCTION TEST 
 
 
 RENAL FUNCTION TEST 
          Blood urea (mg/dl) 
          Serum creatinine  (mg/dl) 
          Serum Electrolytes 
 ECG in all leads 
 Chest x ray PA view 
 USG Abdomen & pelvis 
 DURING FOLLOW UP AT THIRD MONTH 
• History 
• Examination 
• Investigations 
• complete  hemogram and anaemia profile 
• HbA1c levels 
 
 
  
 
 
ANNEXURES – II 
PATIENT CONSENT FORM 
Study title: A STUDY ON INFLUENCE OF IRON DEFICIENCY 
ANEMIA OVER HBA1C LEVELS                                   
Study centre           :   ESIC Medical College - PGIMSR  
Participant name  :                    Age   :     
Sex                          :                    IP No:  
            I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to clarify all my queries and doubts 
and they have been answered to my satisfaction. Investigator explained 
very well about the procedure and I am made aware of the safety, 
advantage and disadvantage of the technique.  
            I understand that my participation in the study is purely voluntary 
and that I am free to withdraw at anytime without giving any reason.           
I have understood that the investigator, regulatory authorities and the 
ethics committee will have access to my health records both in respect to 
current study and any further research that may be conducted in relation 
to it, even if I decide to withdraw from the study. I have understood that 
my identity will not be revealed in anyway and information released to 
third parties or published, unless as required under the law. I agree not to 
restrict the use of any data or results that arise from the study.  
          Without any compulsion I am willing to give consent for the 
participation of myself in this study. 
   
Date:      Signature / thumb impression of patient  
Place:            Patient name: 
Signature of the investigator: 
Name of the investigator       : 
 
 
INFORMATION TO PARTICIPANTS 
Investigator :    Dr.K.Vijaya Durairaj 
Study centre :   ESIC Medical College &  PGIMSR   
K.K.Nagar, Chennai 
 
Title :  A STUDY ON INFLUENCE OF IRON DEFICIENCY 
ANEMIA OVER HBA1C LEVELS   
             You are invited to take part in this research study. We have got 
approval from the IEC. You are asked to participate because you satisfy 
the eligibility criteria. 
Rights and confidentiality 
       The participation in this study is purely voluntary. You have every 
right not to participate in this study. All the data collected in this regard 
from you will be kept discretely and your name will not be revealed at 
any circumstances. 
To contact 
      If you have any doubts and clarification required you can call the 
doctor, VIJAYA DURAIRAJ. at the 9600426353 mobile number at any 
time. 
 
                                          Signature / Thumb Impression of Patient 
                                           Patient Name: 
 
Signature of the Investigator: _______________ 
Name of the Investigator     : _______________ 
 
  
 
 
ANNEXURES – II 
J¨¦uÀ £iÁ® 
ö£¯º :      Á¯x: 
CÚ®:      Põ¨¥mk Gs: 
 {õß Cµzu £¶÷\õuøÚ°ß -»® ö\´²® C¢u B´Âß 
÷{õUPzøu ¦¶¢x öPõs÷hß. ÷©¾® C¢u B´ÂøÚ £ØÔ 
\¢÷uP[PøÍ HØ£k® |ø»°À GÚx \¢÷uP[PøÍ ¬Êø©¯õP 
ÂÍUP¨ ö£Ó»õ® Gß£øu²® AÔ¢x öPõs÷hß. 
 {õß GÚx ö\õ¢u Â¸¨£zvß ÷£¶À C¢u B´ÂØS 
\®©vUQ÷Óß. ÷©¾® G¢u |ø»°¾® {õß C¢u B´Â¼¸¢x 
Â»QU öPõÒÍ»õ® Gß£øu²® AÔ¢x öPõs÷hß. 
 ÷©¾® C¢u B´Â¼¸¢x {õß Â»QUöPõshõ¾® GÚx 
EhÀ £¶÷\õuøÚPÎß ¬iÄPøÍ C¢u B´ÂØS® ©ØÖ® ¤ßÁ¸® 
B´ÄPÐUS® £¯ß£kzu»õ® Gß£øu²® AÔ¢x öPõs÷hß. 
 ÷©¾® AÁ]¯ªßÔ GÚx ö£¯÷µõ, ¦øP¨£h÷©õ G¢u 
|ø»°¾® öÁÎ°h¨£h©õmhõx Gß£øu²® AÔ¢x öPõs÷hß. 
 CøÁ AøÚzx® öu¶¢x® GßÝøh¯ ö\õ¢u Â¸¨£zvß 
÷£¶À {õß C¢u B´ÂØS \®©vUQ÷Óß. 
 
÷uv: 
Ch®:        øPö¯õ¨£® 
MASTER CHART
 
 
ANNEXURES – III 
KEY WORDS TO MASTER CHART 
FBS  - Fasting Blood Glucose 
PPBS          - Post Prandial Blood Glucose 
Hb             -  Hemoglobin 
MCV         -  Mean Corpuscular Volume 
MCH         -  Mean Corpuscular Hemoglobin 
MCHC       -  Mean Corpuscular Hemoglobin Concentration 
SIRON      -  Serum Iron 
TIBC         -  Total Iron Binding Capacity 
ISAT         -  Iron Saturation 
FERRITIN 
HbA1c       -  Glycated Hemoglobin 
C               -  Control Group 
S               -  Study Group 
S1             -  Study Group Pre Correction 
S2             -  Study Group Post Correction 
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1 31 F 78 90 13.4 90.4 27.9 33.2 87.8 306 28.69 185.4 5.5 45 F 87 128 8.1 68.9 23.7 29.2 22.6 397 5.7 5.5 5 12.6 92.3 27.8 33.6 108.78 312 34.86 241.5 5.5
2 22 M 86 97 13.8 95.6 29.2 33.1 99.76 312 31.97 306.5 5.7 37 F 85 93 6.3 62.9 20.4 27.8 13.27 475 2.79 3.9 5.2 12.4 90.5 26.9 34.1 120.43 328 36.71 254.3 5.8
3 26 M 91 126 13.1 94.3 28.7 34.6 104.82 321 32.65 284.3 5.1 21 F 98 132 2.9 50.5 14.8 29.3 24.5 463 5.3 6.2 4.1 12.1 93.4 30.4 33.1 116.31 310 37.51 236.6 5.3
4 20 F 84 106 13.8 88.7 27.3 33.8 96.3 317 30.37 190.7 4.9 39 M 92 97 7.4 68.1 22.4 26.6 9.35 506 1.85 8.2 4 13.1 90.6 29.3 33.6 104.82 317 33.06 279.8 6.1
5 43 F 85 98 14 96.6 29.8 33.5 133.42 315 42.35 244.6 5 32 F 84 98 6.6 72.7 25.1 27.2 17.8 484 3.67 6.8 4.7 12.3 89.5 26.9 33.4 97.65 322 30.32 282.4 6
6 41 F 86 107 12.8 91.2 28.3 33.9 120.34 303 39.71 232.8 5.3 42 F 88 102 8.2 72.5 20.3 28 27.6 445 6.2 9.6 5.1 12.8 95.4 28.8 32.8 89.65 313 28.64 195.3 5.9
7 38 M 97 115 13 91.4 28.1 34.1 132.12 320 41.28 280.3 5.9 46 M 95 100.3 4.9 66.9 17.9 26.7 18.9 412 4.59 7.2 4.6 13 96 29.4 33.2 120.12 328 36.62 254.6 5.5
8 40 M 96 134 13.3 93.1 28.6 33.1 135.62 311 43.6 255.4 5.6 19 F 87 97 8 76 24.1 28.9 27 382 7.1 8.7 4.9 12.9 93.6 29.8 34.2 96.33 305 31.58 210.8 5.8
9 41 F 84 130 13.4 94.2 28.9 33.5 122.73 309 39.71 226.7 5.5 21 F 83 99 7.6 78.1 23.8 28.5 28.2 398 7.08 6.3 5.2 12.3 92.2 29.1 32.6 102.26 310 32.98 251.7 6.1
10 21 F 90 98 13.8 87.9 27.8 33.8 90.6 319 28.4 188.5 5 41 F 88 122 6.6 59.9 16.5 27.5 21.66 406 5.33 5.6 4.2 12.3 91.2 28.2 33.1 124.78 306 40.77 235.5 5.7
11 30 F 92 112 13 91.2 28.2 33.9 104.52 312 33.5 214.6 5.6 28 F 93 112 8.2 72 20.1 28 25.94 480 5.41 4.9 5.08 13.3 87.9 27.8 33.6 99.45 323 30.78 267.8 5.9
12 42 M 88 127 13.2 92.2 29.1 32.9 124.55 306 40.7 229.8 5.3 38 F 90 95 6.8 72.6 23 29.7 29.05 459 6.32 8 4.9 12.2 94.2 28.9 33.5 106.34 319 33.33 212.3 6.2
13 25 M 93 109 13.5 93.6 29.8 32.7 131.42 312 42.12 277.4 5.1 21 F 92 118 7.5 58.6 16.8 28.6 27.93 460 6.07 6.2 4.8 12.5 93.1 28.6 33.1 124.6 303 41.12 204.5 5.6
14 41 F 87 99 12.9 96 29.4 34.2 125.36 305 41.1 207.5 5.4 22 F 85 134 7 55.1 15.8 27.6 26.06 562 4.64 7.1 5.05 12.3 91.4 28.1 34.1 108.65 314 34.6 237.6 5.8
15 44 F 82 135 13.1 95.4 28.8 33.1 122.72 308 39.84 196.4 5.5 48 M 95 124 4.4 49 13.2 26.8 28.66 468 6.12 9.71 5.04 13.2 91.2 28.3 33.9 116.24 310 37.49 266.2 5.5
16 26 F 87 96 12.8 89.5 26.9 32.8 112.6 323 34.86 186.3 5.2 42 M 97 130 7.7 79 22.6 28.7 23.66 398 5.94 8.6 5.01 13 96.6 29.8 33.5 109.81 303 36.24 282.3 5.9
17 36 M 96 106 13.4 90.6 29.3 33.4 124.65 328 38 212.5 5.4 43 F 86 128 8.3 64.8 19.2 29.7 26.12 487 5.36 6.3 5.17 12.9 95.3 27.3 33.8 97.25 312 31.16 238.6 6.3
18 25 F 88 120 13.9 93.4 30.4 33.6 104.88 317 33.08 202.6 5.5 44 F 85 130 8.3 59.3 18 29.3 17.93 417 4.3 9.6 4.8 13.1 96.1 28.7 33.9 108.44 317 34.2 254.6 5.4
19 46 F 84 108 13.3 90.5 26.9 33.1 96.52 330 29.24 177.1 4.9 32 F 84 95 6.6 52.8 14.1 26.7 16.97 502 3.38 3.3 4.3 12.3 86.4 29.2 33.1 114.56 321 35.68 224.5 6.1
20 44 M 92 105 13.4 92.3 27.8 34.5 97.65 328 29.77 176.5 5.6 41 M 90 97 7.3 58.3 17.9 30.7 20.98 502 4.18 4.6 4.7 13.3 91.7 27.9 33.2 122.6 312 39.29 277.4 6
21 20 F 98 126 13 88.5 27.5 33.6 99.38 320 31.05 183.4 5.3 45 M 86 96 4.1 55.2 14.4 26.2 18.4 538 3.42 7.8 5 13.1 87.6 28.7 32.8 132.72 306 43.37 254.4 5.6
22 30 F 85 117 13.2 93.2 28.1 33.9 105.2 314 33.5 198.3 5.4 19 F 78 90 5.8 56.8 20.1 26.8 15.32 450 3.12 3.48 4.2 12.2 91.8 27.6 33.7 115.65 313 36.94 198.5 5.9
23 21 M 78 112 13.6 94.5 29.2 33.5 118.76 312 38.06 233.4 5.6 48 F 98 118 6.7 58 16 27.9 26.52 428 6.2 5.5 4.6 12.1 86.5 29.3 33.2 131.45 316 41.59 237.5 6.2
24 36 F 90 126 12.9 94.6 28.4 32.9 124.6 304 40.98 215.6 5.7 39 F 92 105 7 73.6 21.4 29 14.49 438 3.31 4.3 4.7 12.4 96.1 31.6 34.5 122.33 325 37.64 202.6 5.5
25 25 F 94 114 13.2 93.8 28.6 34.8 106.76 317 33.67 184.67 6 25 F 87 98 8.1 66.2 19.8 29.9 22.8 388 5.88 9.5 4.4 12.9 95.3 30.5 34.3 130.46 331 39.41 196.7 5.4
26 24 F 90 123 13.4 95.5 29.3 33.3 99.97 308 32.45 232.8 5.8 34 M 88 97 6.6 62.4 18 28.8 18.42 422 4.36 7.8 4.8 13.2 94.2 28.5 33.9 96.75 310 31.2 267.5 5.8
27 41 M 85 96 13.8 88.7 27.8 32.9 122.44 314 38.99 244.7 5.3 21 F 96 128 7.8 62.6 20 27.9 17.8 435 4.09 8.4 4.1 12.5 88.6 27.8 33.6 121.37 321 37.8 244.3 5.6
28 41 F 87 124 13.2 89.9 27.6 34.2 98.64 322 30.63 177.6 5.8 47 M 81 109 6.2 60 17 28.4 22 402 5.47 9.2 4.4 13.1 90.2 28.2 34.1 134.76 315 42.78 272.1 5.9
29 25 M 96 132 13.9 91.4 28.7 33.9 130.12 316 41.17 250.6 5.7 42 F 91 108 5.1 59.2 15.7 26.5 21.8 432 5.05 7.8 4.2 12.1 91.3 29.2 32.9 133.14 307 43.36 208.5 6.4
30 20 M 89 94 13.3 88.6 27.9 33.2 121.22 305 39.74 223.5 5.4 41 M 84 96 6.3 62 18.1 27.5 23 397 5.79 6.41 4.7 13.3 89.2 27.9 33.6 109.54 318 34.44 245.6 5.9
31 46 F 78 108 13.6 90.5 28.5 33.5 99.78 312 31.98 206.4 5.3 25 F 97 126 6 65 20.2 29.2 14.38 497 2.89 7.6 5.1 12.2 95.4 29.5 34.3 123.46 309 39.95 262.3 5.3
32 43 F 77 102 13.1 95.7 29.5 32.7 127.34 310 41.07 228.6 5.9 22 F 92 97 7.2 70 22.3 28 26.7 453 5.89 8.5 4.96 12.4 90.5 28.5 32.8 114.33 321 35.61 233.5 6.3
33 30 M 90 127 13.5 89.2 27.9 34.3 115.64 303 38.16 235.6 5.7 43 F 86 98 5.3 57 15.5 27.1 24.5 388 6.31 5.9 4.3 12.2 88.6 27.9 33.5 106.72 315 33.87 212.5 6.4
34 22 M 92 105 13.8 91.2 29.2 33.7 107.82 313 34.44 252.3 5.6 23 F 88 91 8.2 66.6 20.1 29.8 18.5 476 3.89 6.9 4.5 13.1 91.4 28.7 33.2 120.64 322 37.46 272.2 5.5
35 41 F 88 118 13 90 28.2 32.9 120.46 308 39.11 216.5 6.1 40 F 92 116 7.7 73.6 23.5 28 28.6 445 6.43 7.2 4.9 12.7 89.9 27.6 33.9 116.56 306 38.09 242.1 5.3
36 27 F 86 115 13.2 88.6 27.8 34.1 115.74 315 36.74 198.2 5.5 36 M 90 124 8.2 62 17.7 28.3 22.3 437 5.11 6.2 4.5 13.2 88.7 27.8 34.2 132.54 310 42.75 260.5 5.6
37 29 M 92 124 13.9 94.2 28.5 33.6 123.65 322 38.4 215.6 5.2 27 F 77 96 6.5 62.2 18.2 29.2 20.44 459 4.45 3.9 4.7 12.2 95.5 29.3 32.9 127.45 302 42.2 227.6 5.4
38 38 F 97 114 13.5 95.3 30.5 33.9 131.54 312 42.16 220.4 5.1 34 M 78 89 7.9 60.3 19.2 29.8 16.68 449 3.71 5.8 4.1 13.1 93.8 28.6 33.3 99.76 317 31.47 256.7 5.9
39 40 M 84 135 13.4 96.1 31.6 34.3 130.22 314 41.47 234.5 5.3 29 F 89 97 7.7 59.6 19.4 28.5 19.2 465 4.13 7.4 4.6 12.5 94.6 28.4 34.8 103.24 323 31.96 212.4 5.4
40 23 M 91 119 13.8 86.5 29.3 34.5 120.35 306 39.33 267.3 5.5 37 F 96 130 7.6 65 17.7 27.2 22.2 452 4.91 6.8 4.9 12.6 94.5 29.2 32.9 97.48 301 32.38 207.6 5.5
41 27 F 81 108 13.3 91.8 27.6 33.2 97.48 324 30.08 281.4 5.1 41 F 87 97 4.3 56.7 17.3 29.5 16.3 529 3.08 9.8 4.32 12.1 93.3 28.1 33.5 130.22 324 40.19 243.4 5.8
42 33 M 96 120 13.7 87.6 28.7 33.7 103.24 301 34.29 276.6 5.8 45 M 85 114 7.1 72 21.3 27.6 22.8 417 5.46 7.1 4.6 13.1 89.5 27.5 33.9 115.66 306 37.79 262.3 6.2
43 41 F 88 118 13.2 89.8 27.5 32.8 98.75 323 30.57 209.6 6.1 30 F 90 116 7.5 68 19.3 28.5 29.3 511 5.74 8.2 4.62 12.5 96.1 29.6 32.9 123.46 314 39.31 231.5 6.1
44 29 M 87 104 13.9 94.3 28.4 34.6 127.34 317 40.17 230.1 5.4 29 F 94 135 6.4 67 20.5 29 18.6 426 4.36 7.2 4.8 12.4 95.6 28.7 33.8 131.54 312 42.16 196.7 6
45 20 F 92 122 13.2 96.6 29.4 34.2 134.23 302 44.44 255.4 5.2 33 F 90 122 5.4 67 22.5 27.2 9.35 506 1.85 4.9 4.5 12.2 89.6 28.4 34.2 123.65 322 38.4 212.4 5.9
46 22 M 98 104 13.5 95.4 28.7 33.5 119.62 310 38.58 244.6 5.6 35 M 83 125 7.8 68 19.8 29.1 28.3 384 7.4 7.7 4.2 13.3 93.4 29.1 34.4 115.74 315 36.74 270.4 5.3
47 42 F 93 130 13 93.1 28.1 34.6 127.31 306 41.6 234.6 5 32 F 88 99 6.9 70 20.5 29.2 26.4 435 6.07 6.8 4.24 12.2 95.2 28.4 32.9 120.46 308 39.11 231.3 5.7
48 42 M 86 115 13.4 88.6 28.5 34.2 125.49 322 38.97 228.3 5.5 24 F 87 118 8.3 71.7 21.5 28.3 20.61 465 4.43 5.6 4.6 13.1 87.5 29.7 33.7 107.82 313 34.44 227.5 5.4
49 42 F 96 120 13.7 89.5 29.3 33.3 107.66 315 34.17 212.4 5.1 46 M 94 130 5 55 14.8 26.7 15.37 472 3.25 5.6 4.56 13 88.4 29.6 33.4 115.64 303 38.16 282.1 6.1
50 40 F 95 134 13.2 91.4 27.8 33.7 112.43 321 35.02 188.9 5.4 27 F 90 126 6 61.7 18.8 27.4 21.8 392 5.56 7.5 4.7 12.1 92.7 28.1 34.3 127.34 310 41.07 199.4 6.3
51 26 M 87 100 13.8 88.9 28.9 34.1 126.87 309 41.05 230.6 5.7 20 F 88 96 7.3 59.9 17.4 29 24.92 428 5.82 6.2 4.3 12.5 91.6 27.7 32.9 99.78 312 31.98 220.3 5.4
52 30 F 95 130 13.2 94.3 28.2 33.9 109.54 318 34.44 218.8 5.3 37 F 98 124 6.8 65 22.3 27.6 25.44 433 5.87 7.6 4.4 12.3 94.3 27.6 33.1 121.22 305 39.74 252.4 5.9
53 46 M 82 118 13.4 92.2 27.8 33.4 110.72 321 34.49 276.5 5.2 32 M 92 132 7.2 70 23.9 28.2 26.1 426 6.12 5.4 4.2 13.2 89.4 27.9 33.5 130.41 318 41 275.4 5.8
54 29 M 85 99 13.6 88.6 28.5 33.8 105.46 330 31.95 266.2 5.8 31 F 86 94 6.2 66.8 20.4 26.5 18.6 436 4.26 6.9 4.31 12 88.6 28.5 33.8 134.54 311 43.26 221.5 5.4
55 21 F 96 125 13.3 89.4 27.9 33.5 99.85 314 31.79 195.7 5.2 30 F 87 108 6.4 76.2 24.3 28.7 18.88 429 4.4 7.2 4.5 12.2 92.2 27.8 33.4 124.78 306 40.77 208.4 5.6
56 25 F 90 122 13.9 94.3 27.5 32.9 98.64 302 32.66 208.6 5.5 24 F 86 104 6.8 59.7 16.2 27.2 28.36 436 6.5 6.7 4.3 12.1 94.3 28.2 33.9 100.52 321 31.31 271.3 5.5
57 30 F 85 135 13.3 91.6 27.3 32.8 88.97 325 27.37 178.6 5.1 26 F 96 127 7.1 57.5 16.9 29.4 26.9 460 5.84 7.6 4.6 12.6 88.9 28.9 34.1 126.53 303 41.75 234.2 6.2
58 24 F 96 116 13.2 92.7 28.1 34.3 112.78 305 36.97 214.4 5.7 21 F 85 105 6.7 66.1 19.4 27.8 22.5 418 5.38 5.7 4.4 12.1 91.4 27.8 33.7 114.96 323 35.59 255.4 6.1
59 41 M 86 114 13.4 88.4 29.6 33.4 124.66 312 39.95 232.6 5.6 34 F 90 116 7.5 58.6 16.8 28.6 19.6 475 4.12 8.8 4.6 12.4 89.5 29.3 33.3 119.65 320 37.39 211.3 5.4
60 19 M 87 97 13.5 87.5 29.7 33.7 119.12 306 38.92 244.5 4.9 47 M 96 115 5.3 52 13 24.9 25.2 422 5.97 7.4 4.2 13.1 88.6 28.5 34.2 122.75 311 39.46 266.2 5.5
CONTROL GROUP STUDY GROUP PRE CORRECTION STUDY GROUP POST CORRECTION
MASTER CHART
SL
N
O
_C
A
G
E_
C
SE
X
_C
FB
S_
C
P
P
B
S_
C
H
b
_C
M
C
V
_C
M
C
H
_C
M
C
H
C
_C
SI
R
O
N
_C
TI
B
C
_C
IS
A
TN
_C
FE
R
R
IT
IN
_C
H
b
A
1
C
_C
A
G
E_
S
SE
X
_S
FB
S_
S
P
P
B
S_
S
H
b
_S
1
M
C
V
_S
1
M
C
H
_S
1
M
C
H
C
_S
1
SI
R
O
N
_S
1
TI
B
C
_S
1
IS
A
TN
_S
1
FE
R
R
IT
IN
_S
1
H
b
A
1
C
_S
1
H
b
_S
2
M
C
V
_S
2
M
C
H
_S
2
M
C
H
C
_S
2
SI
R
O
N
_S
2
TI
B
C
_S
2
IS
A
TN
_S
2
FE
R
R
IT
IN
_S
2
H
b
A
1
C
_S
2
CONTROL GROUP STUDY GROUP PRE CORRECTION STUDY GROUP POST CORRECTION
61 28 F 86 130 12.8 95.2 28.4 32.9 130.65 303 43.11 253.12 5.8 33 F 85 124 7.7 64.5 19.8 29.7 22.3 415 5.37 8.2 4.9 12.5 93.1 28.1 34.5 131.32 307 42.77 233.1 5.8
62 42 M 92 97 13.8 93.3 29.1 34.4 127.62 312 40.9 246.1 5.5 27 F 82 91 8.1 64.2 20 28.3 24.1 447 5.39 6.8 4.6 12.8 95.4 28.7 33.5 110.34 315 35.02 206.2 5.9
63 40 F 98 129 13.4 89.6 28.4 34.2 133.4 310 43.03 228.7 5.4 37 F 95 135 4.1 55 14.7 27 5.12 483 1.06 7.4 4.1 12.1 96.6 29.4 34.2 123.69 312 39.64 195.6 6.4
64 20 F 88 106 13.2 95.6 28.7 33.8 126.85 309 41.05 232.6 5.9 45 F 87 114 6.6 57.4 16.4 28.5 22.2 456 4.86 3 4.7 12.2 94.3 28.4 34.1 126.85 309 41.05 207.5 6.1
65 39 F 90 124 12.8 97 29.6 32.9 123.69 312 39.64 220.8 5.4 36 M 95 109 4.3 54.2 14.8 27.3 15.8 405 3.9 7.2 4.4 13.2 89.8 27.5 32.9 133.4 310 43.03 258.4 6.4
66 28 F 94 116 13 90.4 27.6 33.8 110.32 315 35.02 192.6 5.2 30 F 96 120 7 64.3 17.8 27.7 26.51 388 6.83 6.4 4.6 12.3 93 28.3 33.1 127.62 312 40.9 223.8 5.6
67 39 M 87 98 13.4 88.7 29.1 34.5 131.32 307 42.77 270.3 5.9 45 M 86 127 7.7 62.4 19.1 29.5 18.6 426 4.36 6.9 5.1 13.3 93.7 27.2 33.2 130.65 303 43.11 276.9 5.7
68 27 M 88 91 13.2 91.4 28.8 34.2 122.79 311 39.48 246.7 5.3 48 M 93 118 6.5 63 17.6 28.1 18.41 435 4.24 5.3 5.2 13 87.4 28.4 34.7 119.12 306 38.92 245.3 5.3
69 23 M 83 98 13.9 92.3 28.3 33.2 119.65 320 37.39 240.8 5.7 39 M 82 93 8.2 65 17.9 27.7 28.37 418 6.78 5.9 4.8 13.2 91.4 27.8 33.5 124.66 312 39.95 224.8 5.8
70 26 F 80 126 13.6 87.6 29.3 32.7 114.98 323 35.59 212.7 5.4 31 F 81 104 7.6 58 16.5 28.7 13.54 503 2.69 7 4.3 12.6 86.5 27.6 34.2 112.78 305 36.97 235.3 5.5
71 36 M 94 120 13.8 88.4 29.1 33.3 125.63 303 41.46 228.5 5.6 40 M 90 130 4.2 49 13.5 27.8 28.5 450 6.33 5.6 4.5 13.1 89.3 28.1 32.8 88.97 325 27.37 197.6 5.9
72 28 F 87 108 12.9 92.5 28.2 34.7 100.45 321 31.29 187.5 5.1 28 F 94 122 6.6 63 16.2 26 21.9 428 5.11 9.1 4.7 12.4 91.7 27.8 33.2 98.64 302 32.66 217.3 6.5
73 38 M 82 114 13.6 89.8 28.7 33.9 124.78 306 40.77 225.4 5.5 49 F 78 97 5.3 66.7 21.1 29.6 17.2 390 4.41 5.9 4 12.1 94.2 28.4 34.1 99.86 314 31.8 245.6 6.3
74 34 M 91 102 13.4 89 28.3 33.4 134.54 311 43.26 265.4 5.6 37 F 86 102 7.8 62.3 18 28.8 24.35 404 6.02 6.7 4.8 12.5 93.6 29.3 33.7 105.46 330 31.95 273.1 6
75 22 F 90 97 12.8 94.5 28.5 34.2 130.41 306 42.61 284.2 5.4 28 F 91 130 5.8 52.9 15.4 29.1 18.3 465 3.93 7.2 4.6 12 90.5 27.5 34.2 110.72 321 34.49 254.2 5.9
76 28 F 78 99 13.8 91.5 27.9 34.6 130.63 324 40.31 273.5 5.9 42 M 83 123 7.2 65.3 19.9 29.4 20.4 440 4.63 7.4 5 13.3 93.6 28.2 33.6 132.56 311 42.62 260.5 5.6
77 19 F 93 122 13 87.6 27.1 34.5 128.2 305 42.03 265.78 5.5 37 M 85 114 6.4 61.1 20.3 28.9 21.6 502 4.3 5.6 4.5 13.1 87.6 27.1 34.5 123.65 306 40.4 255.6 5.8
78 25 M 87 112 13.5 93.6 28.2 33.6 120.77 310 38.95 256.6 5.4 32 F 89 126 6.7 65.5 22.4 27.7 22.9 455 5.03 7.8 4.6 12.3 91.5 27.9 34.3 98.41 312 31.54 225.2 5.6
79 37 F 85 95 13.1 90.5 27.5 34.2 108.46 322 33.68 188.6 5.7 44 F 81 112 8.1 68 19.1 28.3 25.2 425 5.92 6.6 4.7 12.9 94.5 28.5 34.5 120.46 310 38.85 198.1 6.3
80 42 F 95 118 13.2 93.6 29.3 33.7 124.65 310 40.2 246.7 5.3 36 F 96 117 6.3 72 21.6 29 20.7 446 4.64 6.4 5.1 12.3 89.8 28.3 33.4 108.98 303 35.96 267.3 6.2
81 27 M 96 134 13.6 94.2 28.4 34.1 135.64 301 45.06 250.8 5.1 31 F 95 126 7.1 63.7 22.3 28.5 19.8 522 3.79 7.7 4.2 12.5 88.7 28.7 33.9 119.22 332 35.9 231.6 6
82 36 M 81 124 14 91.7 27.8 33.3 128.74 312 41.26 261.2 5.5 42 M 85 105 6.4 65.6 24.3 28.5 21.3 435 4.89 8.6 4.5 13.4 92.5 28.3 34.1 126.78 321 39.49 272.4 5.5
83 38 F 89 130 13.9 89.3 28.1 32.8 123.88 322 38.47 232.4 5.3 27 F 87 108 7 70.2 24 27.6 19.9 438 4.54 7.5 4.4 12.2 88.4 29.1 33.3 125.43 310 40.46 252.3 5.8
84 20 F 85 128 12.8 85.6 27.6 34.2 109.36 313 34.93 253.34 5.2 36 F 93 120 6.1 62.7 22.8 27.9 18.4 414 4.44 8 4.8 12.1 87.6 29.3 32.7 118.74 312 38.05 212.5 5.9
85 27 M 83 130 13.8 91.4 27.8 33.5 130.67 325 40.2 198.7 5.7 33 F 78 106 6.9 64.4 19.5 26.6 19.5 388 5.02 6.4 4.1 12.3 92.3 28.3 33.2 136.54 309 44.18 245.6 5.4
86 38 F 91 115 13.2 87.4 28.4 34.7 131.42 307 42.8 276.4 5.8 23 F 90 96 7.3 75 21.4 27.4 21.5 428 5.02 7.6 4.7 12.6 91.4 28.8 34.2 140.12 306 45.79 228.5 5.5
87 30 M 86 97 13.4 93.7 27.2 33.2 120.45 326 36.94 246.5 5.5 42 M 91 135 8.2 73.2 23.5 27.6 26.1 452 5.77 7.3 4.6 13.2 88.7 29.1 33.7 120.45 326 36.94 235.6 5.8
88 37 M 78 102 13.6 93 28 33.1 140.12 306 45.79 236.8 5.3 40 F 82 98 7.1 74.7 24.5 28.2 25.3 466 5.42 8.5 4.5 12.5 90.4 27.6 33.8 131.42 307 42.8 210.8 5.9
89 44 F 94 116 13.9 89.5 27.8 34.2 136.54 309 44.18 229.7 5.8 19 F 87 109 6 64.8 18.9 24.6 19.1 408 4.68 7 4.24 12.1 93.5 28.4 33.6 130.67 325 40.2 197.7 5.7
90 36 F 90 135 12.8 84.7 27.4 34.4 118.7 312 38.04 241.2 5.7 45 M 94 127 6.7 67.9 20.8 26.5 18.6 435 4.27 6.2 4.8 13.3 95.4 27.7 33.4 109.36 313 34.93 270.9 6.2
91 29 M 81 105 13.8 87.5 28.7 33.5 125.43 310 40.46 235.7 5.6 27 F 79 112 7.4 76.3 22.4 27.8 20.5 464 4.41 6.7 4.2 12.6 94.3 27.3 34.3 123.88 322 38.47 261.4 5.7
92 21 M 93 127 13.4 88.4 28.4 33.8 127.62 321 39.75 218.6 5.4 29 F 80 96 7.2 64 18.7 26.1 21.9 429 5.1 7.5 4.53 12.5 85.6 27.8 33.8 108.48 312 34.76 225.8 6.1
93 33 M 80 98 13.9 90.5 27.8 32.8 119.22 332 35.9 253.4 5.5 21 F 86 130 6.2 67.8 20.4 26.6 17.2 390 4.41 9.2 4.7 12.3 88.9 28.5 33.3 128.74 301 42.77 247.6 6.3
94 26 M 85 128 13.5 88.6 28.5 33.4 108.98 303 35.96 267.2 5.1 36 M 90 134 5.9 64.5 23.5 28.2 20.1 424 4.74 6.3 4.2 13.1 87.7 27.3 34.5 135.64 310 43.75 258.7 5.4
95 27 F 92 109 13 86.3 26.7 34.1 120.46 310 38.85 227.5 5.5 30 F 82 115 6.6 58.9 19.8 24.6 22.1 472 4.68 6.8 4.6 12.2 90.5 27.8 34.2 124.65 322 38.71 216.3 5.8
96 35 F 90 132 13.2 90.8 27.9 33.9 98.41 312 31.54 204.4 5.3 42 M 93 106 7.8 60.4 23.7 28.6 23.35 460 5.07 5.2 4.18 13.4 91.4 28.1 33.1 120.75 307 39.33 244.3 5.9
97 44 F 84 110 13.1 92.1 28.1 35.2 123.65 306 40.4 254.3 5.6 29 F 87 98 8 72.1 24.6 27.1 24.2 444 5.45 5.5 5.12 12.6 87.6 27.4 33.9 128.23 315 40.7 208.6 6
98 20 M 90 128 13.7 91.6 27.7 34.6 132.56 312 42.48 272.4 4.9 24 F 80 105 8.1 75.4 22.6 27.8 22.6 502 4.5 8.3 4.5 12.9 88.6 26.7 34.2 130.63 324 40.31 243.5 5.5
99 29 M 87 120 13.6 90.4 28.3 33.8 130.34 304 42.87 268.6 5.6 29 F 86 126 6.1 68.7 21.7 26.2 19.8 398 4.97 6.6 4.9 12.3 90.2 27.5 33.8 122.34 305 40.11 223.8 5.6
100 46 F 95 108 13.2 89.3 27.2 34.5 107.28 330 32.5 232.5 5.8 36 M 89 118 7 68.2 19.6 27.1 20.8 452 4.6 7.1 4.6 13.2 89.3 27.2 34.4 128.56 322 39.92 262.4 5.3
101 30 M 92 133 13.8 90.2 27.5 33.9 122.56 307 39.92 231.2 5.5 31 F 90 98 7.7 68.6 23.2 28.8 21.4 422 5.07 5.8 5 13.1 90.4 28.3 33.8 119.86 306 39.16 234.4 6.2
102 36 F 78 96 13 88.6 26.7 34.2 95.43 334 28.57 198.4 5.1 44 M 94 130 6.3 62.8 21.4 28.4 13.78 462 2.98 3.8 5.1 13 91.6 27.6 33.9 120.75 322 37.5 227.6 6.1
103 38 F 93 122 13.3 87.5 27.4 34.9 102.78 323 31.82 216.9 5.4 26 F 93 126 5.9 50.8 16.4 27.8 6.8 540 1.25 6.9 4.3 12.1 92.1 28.1 34.5 97.87 311 31.46 260.2 5.7
104 45 M 94 116 14 91.4 28.1 33.1 109.88 315 34.88 230.7 5.6 47 M 78 105 6.3 58.4 29.2 27.5 14.6 436 3.34 4.6 4.56 13.1 90.8 27.9 33.6 104.56 334 31.3 272.1 6.4
105 29 F 90 104 12.8 90.5 27.8 34.6 99.75 312 31.97 224.6 5.8 22 F 92 97 5.6 62 19.5 26.8 13.35 506 2.63 2.9 4.5 12.2 87.3 26.7 34.1 88.72 326 27.21 255.4 5.6
106 33 F 89 115 12.9 87.7 27.3 34.5 124.22 330 37.64 265.4 5.5 28 M 95 114 6.2 68.8 22.5 28.2 24.6 425 5.78 7.2 4.9 13.2 88.6 28.5 33.4 104.56 332 31.49 248.2 5.5
107 27 M 86 99 13.5 88.9 28.5 33.3 126.75 315 40.23 255.2 5.1 39 M 87 127 7.8 72.5 20.5 28 20.13 445 4.52 9.6 5.1 13.4 90.5 27.8 32.8 89.76 306 29.33 203.4 5.6
108 23 F 80 106 13.4 85.6 27.8 33.8 98.9 322 30.71 232.8 5.7 40 F 90 124 5.9 66.9 17.9 26.7 16.4 463 3.54 6.8 4.7 12.1 88.4 28.4 33.8 133.52 310 43.07 226.5 5.9
109 20 M 87 130 13.9 94.3 27.3 34.3 133.55 302 44.22 246.7 5 30 F 84 96 7.6 69.8 21.6 27.8 21.16 395 5.35 9.3 4.9 12.7 87.5 28.7 33.5 136.72 319 42.85 212.4 5.7
110 44 M 93 132 13.8 95.6 27.7 33.4 115.48 319 36.2 234.6 4.9 36 F 90 133 6.8 71.3 20.2 28.3 24.6 428 5.74 5.9 4.5 12 86.4 27.4 34.4 115.48 302 38.23 205.7 6.1
111 39 M 82 96 13.7 93.5 28.4 33.8 136.71 312 43.81 228.9 5.8 23 F 92 132 6.6 68.3 21.4 27.9 18.22 466 3.9 7.4 4.42 12.3 89.5 27.7 34.2 133.53 312 42.79 198.3 6.2
112 29 M 90 124 14 95.3 27.8 34.1 134.52 306 43.96 264.3 5.6 27 F 85 107 6.7 59.8 16.4 27.7 22.65 406 5.57 5.6 4.65 12.2 90.6 28.1 33.2 98.9 315 31.39 233.4 5.7
113 19 F 86 127 13.2 86.4 27.1 33.2 88.72 332 26.72 206.5 5.1 43 M 80 99 7.2 60.4 18.6 28.2 23.1 417 5.53 7.2 4.3 13.2 93.2 27.2 33.5 126.75 330 38.4 271.9 5.5
114 41 F 80 114 12.8 89.2 27.5 33.6 104.56 326 32.07 238.7 5.2 32 F 93 115 8.2 72 20.2 28.3 25.9 460 5.63 4.9 4.7 12.9 89.7 28.2 33.8 124.22 312 39.81 214.6 6.4
115 30 F 96 109 13 92.9 26.8 32.8 97.87 334 29.3 232.3 5.4 45 M 95 104 5.8 69.3 19.6 27.4 18.8 412 4.56 6.9 4.6 13.1 95.1 27.8 33.5 99.75 315 31.66 217.3 5.9
116 45 M 94 105 13.6 93.5 27.5 34.4 120.7 311 38.81 221.4 5.6 36 M 90 95 7.5 68.6 23 28.5 25.5 458 5.56 8 4.9 13.5 93.5 27.5 34.3 109.88 323 34.01 236.4 5.3
117 43 M 88 126 13.9 95.1 27.8 33.5 118.92 322 36.93 233.8 5.3 28 F 86 122 7.1 58.6 16.8 28.6 22.93 425 5.39 6.2 4.8 12.4 92.9 26.8 32.8 102.78 334 30.77 206.4 5.4
118 20 M 86 130 14 89.7 28.2 33.8 128.56 307 41.87 272.1 4.9 20 F 88 108 7 55.4 15.6 28.1 21.6 562 3.84 8.8 4.5 12.1 89.2 27.5 33.6 95.43 307 31.08 228.3 6.1
119 23 F 90 98 13.1 93.2 27.2 33.5 100.42 340 29.53 220.24 5.5 35 M 94 96 5.4 59 16.2 27.6 20.06 478 4.19 9.1 4.72 13.1 86.4 27.1 33.2 122.56 330 37.13 196.5 5.6
120 36 M 95 118 13.8 90.6 28.1 33.2 122.3 305 40.09 264.4 5.4 48 M 96 133 7.7 75.4 21.6 28.3 23.66 396 5.97 8.6 5.1 13.4 95.3 27.8 34.1 127.22 304 41.84 271.2 6.3
